U.S. patent number RE46,791 [Application Number 14/682,512] was granted by the patent office on 2018-04-17 for substituted dihydroquinazolines.
This patent grant is currently assigned to AICURIS ANTI-INFECTIVE CURES GMBH. The grantee listed for this patent is AiCuris GmbH & Co., KG. Invention is credited to Judith Baumeister, Ulrich Betz, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Mario Jeske, Jorg Keldenich, Thomas Lampe, Dieter Lang, Peter Nell, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Tobias Wunberg, Holger Zimmermann.
United States Patent |
RE46,791 |
Wunberg , et al. |
April 17, 2018 |
**Please see images for:
( Certificate of Correction ) ** |
Substituted dihydroquinazolines
Abstract
The invention relates to substituted dihydroquinazolines and to
processes for their preparation and also to their use for preparing
medicaments for the treatment and/or prophylaxis of diseases, in
particular for use as antiviral agents, in particular against
cytomegalo viruses.
Inventors: |
Wunberg; Tobias (Solingen,
DE), Baumeister; Judith (Wuppertal, DE),
Betz; Ulrich (Wuppertal, DE), Jeske; Mario
(Wuppertal, DE), Lampe; Thomas (Dusseldorf,
DE), Nikolic; Susanne (Monheim, DE),
Reefschlager; Jurgen (Oldenburg, DE), Schohe-Loop;
Rudolf (Wuppertal, DE), Sussmeier; Frank
(Wuppertal, DE), Zimmermann; Holger (Wuppertal,
DE), Grosser; Rolf (Leverkusen, DE),
Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy
(Wuppertal, DE), Keldenich; Jorg (Wuppertal,
DE), Lang; Dieter (Velbert, DE), Nell;
Peter (Wuppertal, DE) |
Applicant: |
Name |
City |
State |
Country |
Type |
AiCuris GmbH & Co., KG |
Wuppertal |
N/A |
DE |
|
|
Assignee: |
AICURIS ANTI-INFECTIVE CURES
GMBH (Wuppertal, DE)
|
Family
ID: |
1000002982413 |
Appl.
No.: |
14/682,512 |
Filed: |
April 9, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
Reissue of: |
10832109 |
Apr 26, 2004 |
7196086 |
Mar 27, 2007 |
|
|
Foreign Application Priority Data
|
|
|
|
|
May 2, 2003 [DE] |
|
|
103 19 612 |
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
31/12 (20180101); A61P 31/22 (20180101); A61P
31/00 (20180101); C07D 239/84 (20130101); C07D
239/84 (20130101) |
Current International
Class: |
A61K
31/517 (20060101); C07D 239/84 (20060101); C07D
403/04 (20060101) |
Field of
Search: |
;514/252.17,252
;544/284 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
4320347 |
|
Dec 1994 |
|
DE |
|
1201765 |
|
Feb 2002 |
|
EP |
|
1172361 |
|
May 2002 |
|
EP |
|
1201765 |
|
May 2002 |
|
EP |
|
1568695 |
|
Aug 2005 |
|
EP |
|
9937291 |
|
Jul 1999 |
|
WO |
|
9941253 |
|
Aug 1999 |
|
WO |
|
01/02350 |
|
Jan 2001 |
|
WO |
|
02085869 |
|
Oct 2002 |
|
WO |
|
2004/041790 |
|
May 2004 |
|
WO |
|
2004072048 |
|
Aug 2004 |
|
WO |
|
2004/099212 |
|
Nov 2004 |
|
WO |
|
2004096778 |
|
Nov 2004 |
|
WO |
|
Other References
US Food and Drug Administration Publication: Development of New
Stereoisomeric Drugs. 1992. cited by examiner .
Patani et al. "Bioisosterism: A Rational Approach in Drug Design".
Chem. Rev. 1996; 96:3147-3176. cited by examiner .
Lee et al., "3,4-Dihydroquinoline derivatives as novel selective
T-type Ca2+ channel blockers", Biorg. & Med. Chem. Letters, 14
(2004), pp. 3379-3384. cited by applicant .
Muller et al., "Facilitating the Design of Fluorinated Drugs",
Chemistry & Biology, vol. 16, Nov. 25, 2009, pp. 1130-1133.
cited by applicant .
Muller et al., "Fluorine in Pharmaceuticals: Looking Beyond
Intuition", Science, vol. 317, Sep. 28, 2007, pp. 1880-1886. cited
by applicant .
Vulpetti et al., "Fluorine local environment: from screening to
drug design", Durg Discovery Today, vol. 17, Nos. 15/16, Aug. 2012,
pp. 890-897. cited by applicant .
Wang et al., Fluorine in Pharmaceutical Industry:
Fluorine-Containing Drugs Introduced to the Market in the Last
Decade (2001-2011), Chem. Rev., vol. 114, 2014, pp. 2432-2506.
cited by applicant .
Examiner's search strategy and results in U.S. Pat. No. 7,196,086.
cited by applicant .
AiCuris Press Release, "AiCuris Drug Letermovir (AIC246) meets
primary efficacy endpoints in phase 2 for human cytomegalovirus
(HCMV) prophylaxis in human blood precursor cell recipients," Feb.
14, 2012, 3 pages. cited by applicant .
Cleator, G. M et al., The Herpesviridae in, Principles and Practice
of Clinical Virology 23-26 (Arie J. Zuckerman et al., eds., 5th
ed., 2004). cited by applicant .
Condit, R.C., Principles of Virology in, Fields' Virology 25-57
(David M. Knipe et al., eds., 5th ed., 2007). cited by applicant
.
Desai et al., "Synthesis of substituted quinazolone derivatives as
potential anti-HIV agents (Part III)," Farmaco (1996) 51(5):361-366
(abstract). cited by applicant .
Desai et al., "Synthesis and anti-HIV activity of some
non-nucleoside 2,3-disubstituted quinazoline derivatives (Part-V),"
Indian J. Exp. Biol. (1998) 36(12):1280-1283 (abstract). cited by
applicant .
Freeman, R.B. et al., "Risk Factors for Cytomegalovirus Viremia and
Disease Developing after Prophylaxis in High-Risk Solid Organ
Transplant Recipients," Transplantation, 78(12):1765-1773 (Dec.
2004). cited by applicant .
Gold, D. et al., "Acyclovir Prophylaxis for Herpes Simplex Virus
Infection," Antimicrobial Agents and Chemotherapy, 31(3):361-367
(1987). cited by applicant .
Griesser, Chapter 8, The Importance of Solvates (pp. 211-230), in
the text, Polymorphism in the Pharmaceutical Industry, Hilfiker,
2006. cited by applicant .
Griffiths, P.D., Cytomegalovirus in, Principles and Practice of
Clinical Virology 85-122 (A.J. Zuckerman et al., eds, 5th ed.,
2001). cited by applicant .
Hart, G. et al., "Prophylaxis for CMV should now replace preemptive
therapy in solid organ transplantation," Reviews in Medical
Virology, 11, 73-81 (2001). cited by applicant .
Lischka et al., "Antiviral strategies to combat cytomegalovirus
infections in transplant recipients," Current Opinion in
Pharmacology, (2008) 8:1-8. cited by applicant .
Mutimer, D., "CMV infection of transplant recipients," Journal of
Hepatology, 25:259-269 (1996). cited by applicant .
Nowlin, D.M. et al., Expression of a Human Cytomegalovirus Receptor
Correlates with Infectibility of Cells, Journal of Virology, 65(6):
3114-3121 (1991). cited by applicant .
Pellett, P.E. et al., The Family Herpesviridae: A Brief
Introduction in, Fields' Virology ; 2479-2499, (David M. Knipe et
al., eds., 5th ed., 2007). cited by applicant .
Schmidt, N.J. et al., Plaque Reduction Neutralization Test for
Human Cytomegalovirus Based upon Enhanced Uptake of Neutral Red by
Virus-Infected Cells, Journal of Clinical Microbiology, 4(1): 61-66
(1976). cited by applicant .
Search Report from Ecuadorian Patent Application No. SP 05-6138,
received Dec. 20, 2010, 1 page. cited by applicant .
Tan, "CMV prophylaxis--to do or not to do, that is the question,"
Nephrol. Dial. Transplant (2006) 21:1757-1761. cited by applicant
.
Tykwinski, "Evolution in the Palladium-Catalyzed Cross-Coupling of
sp- and sp2-Hybridized Carbon Atoms," Angew. Chem. Int. Ed. (2003)
42:1566-1568. cited by applicant .
Vippagunta et. al., "Crystalline solids", Advanced Drug Delivery
Review, vol. 48 (2001), pp. 3-26. cited by applicant .
Viral Defense Found., Mission,
http://www.viraldefense.org/mission.htm, downloaded Oct. 20, 2008.
cited by applicant .
Visiting Nurse Assns. of America, "Introduction to Viruses,"
downloaded from
http://www.vnaa.org/vnaa/gen/Germ.sub.--Protection_sub.--Center.sub.-
-Col- d.sub.--and.sub.--Flu.sub.--Resources, downloaded Oct. 22,
2008. cited by applicant .
Waknine, "FDA Approves Longer Valganciclovir CMV Prophylaxis for
Kidney Transplant Patients," WebMD Professional (Aug. 11, 2010) 2
pages. cited by applicant .
Whitley, R.J. et al., "Herpes Simplex Viruses Clinical," Infectious
Diseases, 26:541-555 (1998). cited by applicant .
Wikipedia, "Maribavir," updated Feb. 10, 2009,
http://en.wikipedia.org/wiki/Maribavir, downloaded Mar. 10, 2009.
cited by applicant .
Winston, D.J. et al., "Randomised comparison of ganciclovir and
high-dose acyclovir for long-term cytomegalovirus prophylaxis in
liver-transplant recipients," The Lancet, vol. 346, 69-74 (1995).
cited by applicant .
Wong, "Cytomegalovirus Prophylaxis in Renal Transplant Patients,"
The Hong Kong Medical Diary (2006) 11 (5)14-15. cited by applicant
.
Xin et al., "A practical and efficient intramolecular Michael
addition of ureas to .alpha.,.beta.-unsaturated esters,"
Tetrahedron Lett. (2000) 41(8):1147-1150. cited by applicant .
Zimmermann et al., "Letermovir (AIC246)--A Novel Drug Under
Development for Prevention and Treatment of Cytomegalovirus
Infections Acting via a Novel Mechanism of Action", European
Infectious Disease (2011) 5 (2):112-114. cited by applicant .
U.S. Appl. No. 15/640,661 (not yet published). cited by applicant
.
English language machine translation of WO2001002350A2 published
Jan. 11, 2001 to Bayer AG. cited by applicant .
English language machine translation of WO1999037291A2 published
Jul. 29, 1999 to Bayer AG. cited by applicant .
English language machine translation of DE4320347A1 published Dec.
22, 1994 to Boehringer Mannheim GmbH. cited by applicant .
Misra, V. S., Varshneya, M., "Search for New Antiviral Agents. Part
I. Synthesis of Aryl Sulfamoyl Benzamido Alkyl/Aralkyl Esters", J.
Indian Chem. Soc., 51(II):963-964 (Nov. 1974). cited by applicant
.
Marty et al; The Lancet, vol. 11, Apr. 2011 pp. 284-292. cited by
applicant .
Saito, et al., "A Facile and Efficient Carbodiimide-Mediated
Synthesis of Dihydroquinazolines via a Tandem Nucleophilic
Addition-Intramolecular Hetero Conjugate Addition Annulation
Strategy," Tet. Letts., 37(2): 209-212 (1996).
DOI:10.1016/0040-4039(95)02130-2. cited by applicant .
T. Goldner, 85 Journal of Virology, 10884 (2011). cited by
applicant .
Gribaudo, G., Riera, L., Lembo, D., De Andrea, M., Johnson, L.,
Landolfo, S., "The anticytomegaloviral activity of raltitrexed is
abrogated in quiescent mouse fibroblasts that overexpress the
thymidylate synthase," Virus Research, 73: 57-65 (2001).
DOI:10.1016/S0168-1702(00)00223-9. cited by applicant .
Database Crossfire Beilstein 'Online!, Beilstein Institut Zur
Foerderung Der Wissenschaften, Frankfurt Am Main, DE; BRN
75129-34-9; XP002213430; (CAS Registry No. 75129-34-9) (2003).
cited by applicant .
Database Crossfire Beilstein 'Online!, Beilstein Institut Zur
Foerderung Der Wissenschaften, Frankfurt Am Main, DE; BRN 360648;
Beilstein Reference 4-22-00-05106; XP002213431 (2003). cited by
applicant .
Martinez, A., Gil, C., Castro, A., Bruno, A., Perez, C., Prieto,
C., Otero, J., "Benzothiadiazine dioxide human cytomegalovirus
inhibitors: synthesis and antiviral evaluation of main heterocycle
modified derivatives," Antiviral Chem. Chemo., 14: 107-114 (2003).
cited by applicant .
Wang, et al., "Solid-Phase Synthesis of 3,4-Dihydroquinazoline,"
Tet. Letts., 38(50): 8651-8654 (1997). cited by applicant.
|
Primary Examiner: Jones; Dwayne C.
Attorney, Agent or Firm: Millen, White, Zelano, Branigan,
P.C.
Claims
The invention claimed is:
1. A compound of the formula ##STR00215## in which Ar represents
aryl which may be substituted by 1 to 3 substituents, where the
substituents are selected independently of one another from the
group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl,
alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino,
alkylamino, aminocarbonyl and nitro, where alkyl may be substituted
by 1 to 3 substituents, where the substituents are selected
independently of one another from the group consisting of halogen,
amino, alkylamino, hydroxyl and aryl, R.sup.1 represents hydrogen,
amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro
or trifluoromethyl, R.sup.2 represents hydrogen, alkyl, alkoxy,
alkylthio, cyano, halogen, nitro or trifluoromethyl, R.sup.3
represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano,
halogen, nitro, trifluoromethyl, alkylsulphonyl or
alkylaminosulphonyl R.sup.4 represents hydrogen or alkyl, R.sup.5
represents hydrogen or alkyl or the radicals R.sup.4 and R.sup.5
are attached to carbon atoms directly opposing each other in the
piperazine ring and form a methylene bridge which is optionally
substituted by 1 or 2 methyl groups, R.sup.6 represents alkyl,
alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl,
alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
R.sup.7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl,
carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen,
cyano, hydroxyl or nitro.Iadd., .Iaddend.and R.sup.8 represents
hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl,
alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano,
hydroxyl or nitro, .Iadd.wherein R.sup.1 is attached to the phenyl
ring via the position ortho to the point of attachment of the
phenyl ring,.Iaddend. or a salt, solvate, or solvate of a salt
thereof.
2. A compound according to claim 1, wherein Ar represents phenyl
which may be substituted by 1 to 3 substituents, where the
substituents are selected independently of one another from the
group consisting of C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy,
carboxyl, C.sub.1-C.sub.6-alkylcarbonyl,
C.sub.1-C.sub.6-alkoxycarbonyl, trifluoromethyl, fluorine,
chlorine, bromine, cyano, hydroxyl, amino,
C.sub.1-C.sub.6-alkylamino and nitro, R.sup.1 represents hydrogen,
C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
C.sub.1-C.sub.3-alkylthio, fluorine or chlorine, R.sup.2 represents
hydrogen, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
C.sub.1-C.sub.3-alkylthio, fluorine or chlorine, R.sup.3 represents
C.sub.1-C.sub.4-alkyl, cyano, fluorine, chlorine, nitro,
trifluoromethyl or C.sub.1-C.sub.3-alkylsulphonyl, R.sup.4
represents hydrogen or methyl, R.sup.5 represents hydrogen, R.sup.6
represents C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy, carboxyl,
aminocarbonyl, trifluoromethyl, fluorine, chlorine, cyano, hydroxyl
or nitro, R.sup.7 represents hydrogen, C.sub.1-C.sub.3-alkyl,
C.sub.1-C.sub.3-alkoxy, fluorine, chlorine, cyano or hydroxyl and
R.sup.8 represents hydrogen, C.sub.1-C.sub.3-alkyl,
C.sub.1-C.sub.3-alkoxy, fluorine, chlorine, cyano or hydroxyl.
3. A compound according to claim 1 wherein Ar represents phenyl
which may be substituted by 1 or 2 substituents, where the
substituents are selected independently of one another from the
group consisting of methyl, methoxy, fluorine and chlorine, R.sup.1
represents hydrogen, methyl, methoxy, methylthio, fluorine or
chlorine, R.sup.2 represents hydrogen, R.sup.3 represents methyl,
isopropyl, tert-butyl, cyano, fluorine, chlorine, nitro or
trifluoromethyl, R.sup.4 represents hydrogen, R.sup.5 represents
hydrogen, R.sup.6 represents aminocarbonyl, fluorine, chlorine,
cyano or hydroxyl, R.sup.7 represents hydrogen and R.sup.8
represents hydrogen, fluorine or chlorine.
4. A compound according to claim 1, wherein R.sup.1 represents
hydrogen, methyl, methoxy or fluorine.
5. A compound according to claim 1, wherein R.sup.1 represents
methoxy.
.[.6. A compound according to claim 1, wherein R.sup.1 is attached
to the phenyl ring via the position ortho to the point of
attachment of the phenyl ring..].
7. A compound according to claim 1, wherein R.sup.2 represents
hydrogen.
8. A compound according to claim 1, wherein R.sup.3 represents
trifluoromethyl, chlorine, methyl, isopropyl or tert-butyl.
9. A compound according to claim 1, wherein R.sup.3 represents
trifluoromethyl, chlorine or methyl.
10. A compound according to claim 1, wherein .[.R.sup.1 is attached
to the phenyl ring via the position ortho to the point of
attachment of the phenyl ring and.]. R.sup.3 is attached to the
phenyl ring via the position meta to the point of attachment of the
phenyl ring, which position is opposite to that of R.sup.1.
11. A compound according to claim 1, wherein R.sup.4 and R.sup.5
represent hydrogen.
12. A compound according to claim 1, wherein R.sup.6 represents
fluorine.
13. A compound according to claim 1, wherein R.sup.7 represents
hydrogen.
14. A compound according to claim 1, wherein R.sup.8 represents
hydrogen, methyl or fluorine.
15. A compound according to claim 1, wherein Ar represents phenyl
which may be substituted by 1 or 2 substituents, where the
substituents are selected independently of one another from the
group consisting of methyl, methoxy, fluorine and chlorine.
16. A process for preparing a compound of .[.the.]. formula (I)
.[.according to claim 1, wherein.]. .Iadd.or a salt, solvate, or
solvate of a salt thereof ##STR00216## in which Ar represents aryl
which may be substituted by 1 to 3 substituents, where the
substituents are selected independently of one another from the
group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl,
alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino,
alkylamino, aminocarbonyl and nitro, where alkyl may be substituted
by 1 to 3 substituents, where the substituents are selected
independently of one another from the group consisting of halogen,
amino, alkylamino, hydroxyl and aryl, R.sup.1 represents hydrogen,
amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro
or trifluoromethyl, R.sup.2 represents hydrogen, alkyl, alkoxy,
alkylthio, cyano, halogen, nitro or trifluoromethyl, R.sup.3
represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano,
halogen, nitro, trifluoromethyl, alkylsulphonyl or
alkylaminosulphonyl R.sup.4 represents hydrogen or alkyl, R.sup.5
represents hydrogen or alkyl or the radicals R.sup.4 and R.sup.5
are attached to carbon atoms directly opposing each other in the
piperazine ring and form a methylene bridge which is optionally
substituted by 1 or 2 methyl groups, R.sup.6 represents alkyl,
alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl,
alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
R.sup.7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl,
carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen,
cyano, hydroxyl or nitro, and R.sup.8 represents hydrogen, alkyl,
alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl,
trifluoromethyl, halogen, cyano, hydroxyl or nitro, said process
comprising: reacting .Iaddend.a compound of .[.the.]. formula
.Iadd.II.Iaddend. ##STR00217## in which Ar, R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as
defined in claim 1 and R.sup.9 represents alkyl selected from the
group consisting of methyl, ethyl, and tert-butyl, .[.is reacted.].
with a base or an acid.
17. A medicament comprising a compound according to claim 1 in
combination with an inert non-toxic pharmaceutically acceptable
auxiliary.
18. A method for treating infection by Herpes viridae in humans and
animals by administering an antivirally effective amount of at
least one compound according to claim 1, or a medicament according
to claim 17.
19. The method according to claim 18, wherein the .[.Heprpes.].
.Iadd.Herpes .Iaddend.viridae is .[.selected form the group
consisting of cytomegalovirus.]. .Iadd.a cytomegalovirus
.Iaddend.(CMV) .[.and human cytomegalovirus (HCMV) or another
representative of the group of the Herpes viridae.]..
.Iadd.20. The method according to claim 18, wherein the Herpes
viridae is human cytomegalovirus (HCMV)..Iaddend.
.Iadd.21. A method for treating infection by HCMV in humans by
administering an antiviral effective amount of the compound:
##STR00218## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.22. The method according to claim 21, wherein said compound
is: ##STR00219## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.23. The compound of claim 1, wherein said compound is:
##STR00220## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.24. The compound of claim 1, wherein said compound is:
##STR00221## .Iaddend.
.Iadd.25. The compound of claim 1, wherein said compound is a
physiologically acceptable salt of: ##STR00222## .Iaddend.
.Iadd.26. The compound of claim 1, wherein said compound is:
##STR00223## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.27. The compound of claim 1, wherein said compound is:
##STR00224## .Iaddend.
.Iadd.28. The compound of claim 1, wherein said compound is a
physiologically acceptable salt of the compound: ##STR00225##
.Iaddend.
.Iadd.29. The compound of claim 1, wherein said compound is of the
formula: ##STR00226## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.7, R.sup.8, and Ar are as defined in claim 6, and
R.sup.6 is fluorine; or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.30. The compound of claim 3, wherein said compound is of the
formula: ##STR00227## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.7, R.sup.8, and Ar are as defined in claim 3, and
R.sup.6 is fluorine; or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.31. The medicament of claim 17, wherein said compound is:
##STR00228## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.32. The medicament of claim 17, wherein said compound is:
##STR00229## or a physiologically acceptable salt
thereof..Iaddend.
.Iadd.33. The compound of claim 1, which is the compound of formula
(I) or a physiologically acceptable salt thereof..Iaddend.
.Iadd.34. A compound according to claim 1, wherein R.sup.6
represents alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl,
alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano,
hydroxyl or nitro..Iaddend.
.Iadd.35. A compound according to claim 30, wherein R.sup.1 is
methoxy..Iaddend.
.Iadd.36. A compound according to claim 30, wherein R.sup.3 is
trifluoromethyl, chlorine or methyl..Iaddend.
.Iadd.37. A compound according to claim 36, wherein R.sup.3 is
trifluoromethyl..Iaddend.
.Iadd.38. A compound according to claim 30, wherein R.sup.8 is
hydrogen..Iaddend.
.Iadd.39. A compound according to claim 30, wherein R.sup.1 is
methoxy and wherein R.sup.3 is trifluoromethyl, chlorine or
methyl..Iaddend.
.Iadd.40. A compound according to claim 30, wherein R.sup.3 is
trifluoromethyl and is attached to the phenyl ring via the position
meta to the point of attachment of the phenyl ring, which position
is opposite to that of R.sup.1..Iaddend.
.Iadd.41. A compound according to claim 26, having an enantiomeric
excess of more than 90%..Iaddend.
.Iadd.42. A compound according to claim 27, having an enantiomeric
excess of more than 90%..Iaddend.
.Iadd.43. A compound according to claim 28, having an enantiomeric
excess of more than 90%..Iaddend.
.Iadd.44. A compound according to claim 2, wherein R.sup.6
represents C.sub.1-C.sub.3-alkoxy, carboxyl, aminocarbonyl,
trifluoromethyl, fluorine, chlorine, cyano, hydroxyl or
nitro..Iaddend.
Description
The invention relates to substituted dihydroquinazolines and to
processes for their preparation and also to their use for preparing
medicaments for the treatment and/or prophylaxis of diseases, in
particular for use as antiviral agents, in particular against
cytomegalo viruses.
The synthesis of dihydroquinazolines is described in Saito T., et
al. Tetrahedron Lett., 1996, 37, 209-212 and in Wang F., et al.
Tetrahedron Lett., 1997, 38, 8651-8654.
Although agents with antiviral activity and a different structure
are available on the market, it is always possible for resistance
to develop. Novel agents for an effective therapy are therefore
desirable.
One object of the present invention is therefore to provide novel
compounds having the same or improved antiviral effect for the
treatment of viral infective diseases in humans and animals.
It has been found, surprisingly, that the substituted
dihydroquinazolines described in the present invention have
antiviral effect.
The present invention provides compounds of the formula
##STR00001## in which Ar represents aryl which may be substituted
by 1 to 3 substituents, where the substituents are selected
independently of one another from the group consisting of alkyl,
alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl,
trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino,
aminocarbonyl and nitro, where alkyl may be substituted by 1 to 3
substituents, where the substituents are selected independently of
one another from the group consisting of halogen, amino,
alkylamino, hydroxyl and aryl, or two of the substituents on the
aryl radical together with the carbon atoms to which they are
attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane
ring, and any third substituent present is selected independently
from the group mentioned, R.sup.1 represents hydrogen, amino,
alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or
trifluoromethyl, R.sup.2 represents hydrogen, alkyl, alkoxy,
alkylthio, cyano, halogen, nitro or trifluoromethyl, R.sup.3
represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano,
halogen, nitro, trifluoromethyl, alkylsulphonyl or
alkylaminosulphonyl or one of the radicals R.sup.1, R.sup.2 and
R.sup.3 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro
or trifluoromethyl and the other two together with the carbon atoms
to which they are attached form a 1,3-dioxolane, a cyclopentane
ring or a cyclohexane ring, R.sup.4 represents hydrogen or alkyl,
R.sup.5 represents hydrogen or alkyl or the radicals R.sup.4 and
R.sup.5 are attached to carbon atoms directly opposing each other
in the piperazine ring and form a methylene bridge which is
optionally substituted by 1 or 2 methyl groups, R.sup.6 represents
alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl,
alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano,
hydroxyl or nitro, R.sup.7 represents hydrogen, alkyl, alkoxy,
alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl,
trifluoromethyl, halogen, cyano, hydroxyl or nitro and R.sup.8
represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl,
alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano,
hydroxyl or nitro, and their salts, their solvates and the solvates
of their salts.
Compounds according to the invention are the compounds of the
formula (I) and their salts, solvates and solvates of the salts,
compounds mentioned below as embodiment(s) and their salts,
solvates and solvates of the salts, unless the compounds below,
embraced by formula (I), are already salts, solvates and solvates
of the salts.
The compounds according to the invention may, depending on their
structure, exist in stereoisomeric forms (enantiomers,
diastereomers). The invention therefore relates to the enantiomers
or diastereomers and respective mixtures thereof. The
stereoisomerically pure constituents can be isolated in a known
manner from such mixtures of enantiomers and/or diastereomers.
If the compounds according to the invention may exist in tautomeric
forms, the present invention embraces all such tautomeric
forms.
Salts which are preferred for the purposes of the present invention
are physiologically acceptable salts of the compounds according to
the invention. However, the invention also embraces salts which are
per se not suitable for pharmaceutical applications but can be
used, for example, for isolating or purifying the compounds
according to the invention.
Physiologically acceptable salts of the compounds according to the
invention include acid addition salts of mineral acids, carboxylic
acids and sulphonic acids, for example salts of hydrochloric acid,
hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic
acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic
acid, naphthalenedisulphonic acid, acetic acid, trifluoroacetic
acid, propionic acid, lactic acid, tartaric acid, malic acid,
citric acid, fumaric acid, maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds according to the
invention also include salts of customary bases, such as, by way of
example and preferably, alkali metal salts (for example sodium and
potassium salts), alkaline earth metal salts (for example calcium
and magnesium salts) and ammonium salts derived from ammonia or
organic amines having 1 to 16 carbon atoms, such as, by way of
example and preferably, ethylamine, diethylamine, triethylamine,
ethyldiisopropylamine, monoethanolamine, diethanolamine,
triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine,
dibenzylamine, N-methylmorpholine, arginine, lysine,
ethylenediamine and N-methylpiperidine.
Solvates refer for the purposes of the invention to those forms of
the compounds according to the invention which form a complex in
the solid or liquid state by coordination with solvent molecules.
Hydrates are a special form of solvates in which the coordination
takes place with water.
For the purposes of the present invention, unless specified
otherwise, the substituents have the following meanings:
Alkyl per se and "alk" and "alkyl" in alkoxy, alkylamino,
alkylcarbonyl, alkylsulphonyl, alkylaminosulphonyl and
alkoxycarbonyl are a straight-chain or branched alkyl radical
having generally 1 to 6, preferably 1 to 4, particularly preferably
1 to 3, carbon atoms, by way of example and preferably methyl,
ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
Alkoxy is, by way of example and preferably, methoxy, ethoxy,
n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
Alkylamino is an alkylamino radical having one or two alkyl
substituents (chosen independently of one another), by way of
example and preferably methylamino, ethylamino, n-propylamino,
isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino,
N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino,
N-methyl-N-n-propylamino, N-isopropyl-N-n-propyl-amino,
N-tert-butyl-N-methylamino, N-ethyl-N-n-pentylamino and
N-n-hexyl-N-methylamino. C.sub.1-C.sub.3-alkylamino is, for
example, a monoalkylamino radical having 1 to 3 carbon atoms or a
dialkylamino radical having in each case 1 to 3 carbon atoms per
alkyl substituent.
Alkylsulphonyl is, by way of example and preferably,
methylsulphonyl, ethylsulphonyl, n-propyl-sulphonyl,
isopropylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl and
n-hexylsulphonyl.
Alkylaminosulphonyl is an alkylaminosulphonyl radical having one or
two alkyl substituents (chosen independently of one another), by
way of example and preferably methylaminosulphonyl,
ethylaminosulphonyl, n-propylaminosulphonyl,
isopropylaminosulphonyl, tert-butylaminosulphonyl,
n-pentylaminosulphonyl, n-hexyl-aminosulphonyl,
N-N-dimethylaminosulphonyl, N-N-diethyl-aminosulphonyl,
N-ethyl-N-methylaminosulphonyl,
.[.N-methyl-N-n-propylamiinosulphonyl.].
.Iadd.N-methyl-N-n-propylaminosulphonyl.Iaddend.,
N-isopropyl-N-n-propyl-aminosulphonyl,
N-tert-butyl-N-methylaminosulphonyl,
N-ethyl-N-n-pentyl-aminosulphonyl and
N-n-hexyl-N-methylaminosulphonyl.
C.sub.1-C.sub.3-alkylaminosulphonyl is, for example, a
monoalkylaminosulphonyl radical having 1 to 3 carbon atoms or a
dialkylaminosulphonyl radical having in each case 1 to 3 carbon
atoms per alkyl substituent.
Alkylcarbonyl is, by way of example and preferably, acetyl and
propanoyl.
Alkoxycarbonyl is, by way of example and preferably,
methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl,
isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and
n-hexoxy-carbonyl.
Aryl is a mono- to tricyclic aromatic carbocyclic radical having
generally 6 to 14 carbon atoms; by way of example and preferably
phenyl, naphthyl and phenanthrenyl.
Halogen is fluorine, chlorine, bromine and iodine, preferably
fluorine and chlorine.
A symbol * on a carbon atoms means that the compound, with respect
to the configuration at this carbon atom, is present in
enantiomerically pure form which, for the purposes of the present
invention, is to be understood as meaning an enantiomeric excess of
more than 90% (>90% ee).
Preference is given to those compounds of the formula (I) in which
Ar represents phenyl which may be substituted by 1 to 3
substituents, where the substituents are selected independently of
one another from the group consisting of C.sub.1-C.sub.6-alkyl,
C.sub.1-C.sub.6-alkoxy, carboxyl, C.sub.1-C.sub.6-alkylcarbonyl,
C.sub.1-C.sub.6-alkoxycarbonyl, trifluoromethyl, fluorine,
chlorine, bromine, cyano, hydroxyl, amino,
C.sub.1-C.sub.6-alkylamino and nitro, or two of the substituents on
the phenyl radical together with the carbon atoms to which they are
attached form a 1,3-dioxolane and any third substituent present is
selected independently from the group mentioned, R.sup.1 represents
hydrogen, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
C.sub.1-C.sub.3-alkylthio, fluorine or chlorine, R.sup.2 represents
hydrogen, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
C.sub.1-C.sub.3-alkylthio, fluorine or chlorine, R.sup.3 represents
C.sub.1-C.sub.4-alkyl, cyano, fluorine, chlorine, nitro,
trifluoromethyl or C.sub.1-C.sub.3-alkylsulphonyl, or one of the
radicals R.sup.1, R.sup.2 and R.sup.3 represents hydrogen,
C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy, cyano, halogen,
nitro or trifluoromethyl and the other two together with the carbon
atoms to which they are attached form a cyclopentane ring or a
cyclohexane ring, R.sup.4 represents hydrogen or methyl, R.sup.5
represents hydrogen, R.sup.6 represents C.sub.1-C.sub.3-alkyl,
C.sub.1-C.sub.3-alkoxy, carboxyl, aminocarbonyl, trifluoromethyl,
fluorine, chlorine, cyano, hydroxyl or nitro, R.sup.7 represents
hydrogen, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy, fluorine,
chlorine, cyano or hydroxyl and R.sup.8 represents hydrogen,
C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy, fluorine, chlorine,
cyano or hydroxyl.
Among these, particular preference is given to those compounds of
the formula (I), in which Ar represents phenyl which may be
substituted by 1 or 2 substituents, where the substituents are
selected independently of one another from the group consisting of
methyl, methoxy, fluorine and chlorine, R.sup.1 represents
hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,
R.sup.2 represents hydrogen, R.sup.3 represents methyl, isopropyl,
tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
R.sup.4 represents hydrogen, R.sup.5 represents hydrogen, R.sup.6
represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,
R.sup.7 represents hydrogen and R.sup.8 represents hydrogen,
fluorine or chlorine.
Among these, particular preference is also given to those compounds
of the formula (I), in which Ar represents phenyl which may be
substituted by 1 or 2 substituents, where the substituents are
selected independently of one another from the group consisting of
methyl, methoxy, fluorine and chlorine,.[.-.]. R.sup.1 represents
hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,
R.sup.2 represents hydrogen, R.sup.3 represents methyl, tert-butyl,
cyano, fluorine, chlorine, nitro or trifluoromethyl, R.sup.4
represents hydrogen, R.sup.5 represents hydrogen, R.sup.6
represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,
R.sup.7 represents hydrogen and R.sup.8 represents hydrogen,
fluorine or chlorine.
Among these, very particular preference is given to those compounds
of the formula (I), in which Ar represents phenyl which may be
substituted by 1 or 2 substituents, where the substituents are
selected independently of one another from the group consisting of
methyl, methoxy, fluorine and chlorine, R.sup.1 represents hydrogen
or methoxy, R.sup.2 represents hydrogen, R.sup.3 represents methyl,
tert-butyl, chlorine or trifluoromethyl, R.sup.4 represents
hydrogen, R.sup.5 represents hydrogen, R.sup.6 represents
aminocarbonyl or fluorine, R.sup.7 represents hydrogen and R.sup.8
represents hydrogen or fluorine.
Preference is also given to those compounds of the formula (I), in
which R.sup.1 represents hydrogen, methyl, methoxy or fluorine.
Among these, particular preference is given to those compounds of
the formula (I), in which R.sup.1 represents methoxy.
Preference is also given to those compounds of the formula (I) in
which R.sup.1 is attached to the phenyl ring via the position ortho
to the point of attachment of the phenyl ring. For the purposes of
the present invention, the point of attachment of the phenyl ring
substituted by radicals R.sup.1, R.sup.2 and R.sup.3 is to be
understood as meaning the carbon atom of the phenyl ring which,
according to formula (I), is attached to one of the two nitrogen
atoms of the dihydroquinazoline.
Particular preference is given to those compounds of the formula
(I), in which R.sup.1 represents methoxy and R.sup.1 is attached to
the phenyl ring via the position ortho to the point of attachment
of the phenyl ring.
Preference is also given to those compounds of the formula (I) in
which R.sup.2 represents hydrogen.
Preference is also given to those compounds of the formula (I) in
which R.sup.3 represents trifluoromethyl, chlorine, methyl,
isopropyl or tert-butyl.
Among these, particular preference is given to those compounds of
the formula .[.(D).]. .Iadd.(I) .Iaddend.in which R.sup.3
represents trifluoromethyl, chlorine or methyl.
Among these, very particular preference is given to those compounds
of the formula (I) in which R.sup.3 represents trifluoromethyl.
Preference is also given to those compounds of the formula (I) in
which R.sup.1 is attached to the phenyl ring via the position ortho
to the point of attachment of the phenyl ring and R.sup.3 is
attached to the phenyl ring via the position meta to the point of
attachment of the phenyl ring, which position is opposite to that
of R.sup.1.
Particular preference is given to those compounds of the formula
(I) in which R.sup.1 is attached to the phenyl ring via the
position ortho to the point of attachment of the phenyl ring,
R.sup.3 represents trifluoromethyl, chlorine or methyl and R.sup.3
is attached to the phenyl ring via the position meta to the point
of attachment of the phenyl ring, which position is opposite to
that of R.sup.1.
Among these, particular preference is given to those compounds of
the formula (I) in which R.sup.1 is attached to the phenyl ring via
the position ortho to the point of attachment of the phenyl ring,
R.sup.3 represents trifluoromethyl and R.sup.3 is attached to the
phenyl ring via the position meta to the point of attachment of the
phenyl ring, which position is opposite to that of R.sup.1.
Preference is also given to those compounds of the formula (I) in
which R.sup.4 and R.sup.5 represent hydrogen.
Preference is also given to those compounds of the formula (I) in
which R.sup.6 represents fluorine.
Particular preference is given to those compounds of the formula
(I) in which R.sup.6 represents fluorine and R.sup.6 is, as
described in formula
##STR00002## attached to the aromatic radical of the
dihydroquinazoline.
Preference is also given to those compounds of the formula (I) in
which R.sup.7 represents hydrogen.
Among these, particular preference is given to those compounds of
the formula (I) in which R.sup.8 represents hydrogen, methyl or
fluorine.
Among these, very particular preference is given to those compounds
of the formula (I) in which R.sup.8 represents hydrogen.
Preference is also given to those compounds of the formula (I) in
which Ar represents phenyl which may be substituted by 1 or 2
substituents, where the substituents are selected independently of
one another from the group consisting of methyl, methoxy, fluorine
and chlorine.
The particular radical definitions given in the respective
combinations or preferred combinations of radicals are,
independently of the combinations of radicals given in each case,
also replaced by radical definitions of other combinations.
Very particular preference is given to combinations of two or more
of the preferred ranges mentioned above.
The invention furthermore provides a process for preparing the
compounds of the formula (I), which comprises reacting compounds of
the formula
##STR00003## in which Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined above and
R.sup.9 represents alkyl, preferably methyl or ethyl or tert-butyl,
with bases or acids.
In the case of methyl and ethyl, the reaction is generally carried
out using bases in inert solvents, preferably in a temperature
range of from room temperature to the reflux temperature of the
solvent, at atmospheric pressure.
Suitable bases are, for example, alkali metal hydroxides, such as
sodium hydroxide, lithium hydroxide or potassium hydroxide, or
alkali metal carbonates, such as caesium carbonate, sodium
carbonate or potassium carbonate, if appropriate in aqueous
solution; preference is given to sodium hydroxide in water.
Inert solvents are, for example, ethers, such as
1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl
ether or diethylene glycol dimethyl ether, alcohols, such as
methanol, ethanol, n-propanol, isopropanol, n-butanol or
tert-butanol, or mixtures of solvents; preference is given to
dioxane or tetrahydrofuran.
In the case of tert-butyl, the reaction is generally carried out
using acids in inert solvents, preferably in a temperature range of
from 0.degree. C. to 40.degree. C., at atmospheric pressure.
Here, suitable acids are hydrogen chloride in dioxane, hydrogen
bromide in acetic acid or trifluoroacetic acid in methylene
chloride.
The compounds of the formula (II) are known or can be prepared by
reacting compounds of the formula
##STR00004## in which R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are as
defined above in a two-step reaction initially with compounds of
the formula
##STR00005## in which R.sup.1, R.sup.2 and R.sup.3 are as defined
above and then with compounds of the formula
##STR00006## in which Ar, R.sup.4 and R.sup.5 are as defined
above.
Both steps of the reaction are generally carried out in inert
solvents, preferably in a temperature range of from room
temperature to 100.degree. C., at atmospheric pressure. In the
second step, if appropriate, silica gel is added to the reaction
mixture. The reaction is preferably carried out with work-up
between the first and the second step.
Suitable inert solvents are, for example, halogenated hydrocarbons,
such as methylene chloride, trichloromethane, carbon tetrachloride,
trichloroethane, tetrachloroethane, 1,2-dichloroethane or
trichloroethylene, ethers, such as diethyl ether, methyl tert-butyl
ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol
dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons,
such as benzene, xylene, toluene, hexane, cyclohexane or mineral
oil fractions, or other solvents, such as dimethylformamide,
dimethylacetamide, acetonitrile or ethyl acetate, or mixtures of
solvents; preference is given to methylene chloride.
The compounds of the formula (IV) are known or can be synthesized
by known processes from the corresponding starting materials.
The compounds of the formula (V) are known or can be synthesized by
known processes from the corresponding starting materials, for
example by a Buchwald-Hartwig reaction according to the synthesis
scheme below (review in: C. G. Frost, P. Mendonca, J. Chem. Soc.,
Perkin Trans I, 1998, 2615-2623): Buchwald-Hartwig reaction:
##STR00007##
The starting materials required for this purpose are known or can
be synthesized by known processes from the corresponding starting
materials.
The compounds of the formula .[.(M).]. .Iadd.(III) .Iaddend.are
known or can be prepared by reacting compounds of the formula
##STR00008## in which R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are as
defined above with triphenylphosphine and carbon tetrachloride.
The reaction is generally carried out in inert solvents, in the
presence of a base, preferably in a temperature range of from room
temperature to 50.degree. C., at atmospheric pressure.
Suitable inert solvents are, for example, ethers, such as diethyl
ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane,
tetrahydrofuran, glycol dimethyl ether or diethylene glycol
dimethyl ether, hydrocarbons, such as benzene, xylene, toluene,
hexane, cyclohexane or mineral oil fractions, or other solvents,
such as dimethylformamide, dimethylacetamide, acetonitrile or
pyridine; preference is given to acetonitrile.
Suitable bases are, for example, alkali metal and alkaline earth
metal carbonates, such as caesium carbonate, sodium carbonate or
potassium carbonate, or amines, such as triethylamine,
diisopropylethylamine, N-methylmorpholine or pyridine; preference
is given to triethylamine.
The compounds of the formula (VI) are known or can be synthesized
by known processes from the corresponding starting materials, for
example by a Heck reaction or a .[.Wittig-Homer.].
.Iadd.Wittig-Horner .Iaddend.reaction, according to the synthesis
schemes below: Heck reaction:
##STR00009## Wittig-Horner reaction:
##STR00010##
The starting materials required for this purpose are known or can
be synthesized by known processes from the corresponding starting
materials.
The preparation of the compounds according to the invention can be
illustrated by the synthesis scheme below. Synthesis scheme:
##STR00011##
The compounds of the general formula (I) according to the invention
show a surprising range of effects which could not have been
predicted. They show an antiviral effect on representatives of the
group of the Herpes viridae (Herpes viruses), especially on
cytomegalo viruses (CMV), in particular, on human cytomegalovirus
(HCMV).
Areas of indication which may be mentioned by way of example are:
1) Treatment and prophylaxis of HCMV infections in AIDS patients
(retinitis, pneumonitis, gastrointestinal infections). 2) Treatment
and prophylaxis of cytomegalovirus infections in bone-marrow and
organ transplantations which develop often life-threatening HCMV
pneumonitis or encephalitis, and gastrointestinal and systemic HCMV
infections. 3) Treatment and prophylaxis of HCMV infections in
neonates and infants. 4) Treatment of an acute HCMV infection in
pregnant women. 5) Treatment of HCMV infection in immunosuppressed
patients associated with cancer and cancer therapy. 6) Treatment of
HCMV-positive cancer patients with the aim to reduce HCMV-mediated
tumour progression (cf. J. Cinatl, et al., FEMS Microbiology
Reviews 2004, 28, 59-77).
The present invention further provides the use of the compounds
according to the invention for the treatment and/or prophylaxis of
diseases, especially of infections with viruses, in particular the
viruses mentioned above, and the infective diseases caused by these
infections. Hereinbelow, a viral infection is to be understood as
including both an infection with a virus and a disease caused by an
infection with a virus.
The present invention also provides the use of the compounds
according to the invention for the treatment and/or prophylaxis of
disorders, in particular the disorders mentioned above.
The present invention also provides the use of the compounds
according to the invention for preparing a medicament for the
treatment and/or prophylaxis of disorders, in particular the
disorders mentioned above.
The compounds according to the invention are preferably used for
preparing medicaments suitable for the prophylaxis and/or treatment
of infections with a representative of the group of the Herpes
viridae, in particular a cytomegalovirus, in particular the human
cytomegalovirus.
The present invention also provides a method for the treatment
and/or prophylaxis of disorders, in particular the disorders
mentioned above, using an antivirally effective amount of the
compounds according to the invention.
The present invention also provides medicaments comprising at least
one compound according to the invention and at least one or more
further active compounds, in particular for the treatment and/or
prophylaxis of the disorders mentioned above. Active compounds
suitable for combinations are, by way of example and preferably:
antiviral active compounds, such as gancyclovir or acyclovir.
The compounds according to the invention can act systemically
and/or locally. For this purpose, they can be administered in a
suitable way, such as, for example, by the oral, parenteral,
pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal,
transdermal, conjunctival or otic route, or as implant or
stent.
For these administration routes, it is possible to administer the
compounds according to the invention in suitable administration
forms.
Suitable for oral administration are known administration forms
which deliver the compounds according to the invention rapidly
and/or in modified form and which comprise the compounds according
to the invention in crystalline and/or amorphous and/or dissolved
form, such as, for example, tablets (uncoated or coated tablets,
for example tablets provided with enteric coatings or coatings
which dissolve slowly or are insoluble and which control the
release of the compound according to the invention), tablets which
disintegrate rapidly in the oral cavity and/or films/wafers,
films/lyophylisates, capsules (for example Hart or soft gelatin
capsules), sugar-coated tablets, granules, pellets, powders,
emulsions, suspensions, aerosols or solutions.
Parenteral administration can take place with avoidance of an
adsorption step (for example intravenously, intraarterially,
intracardially, intraspinally or intralumbally) or with inclusion
of absorption (for example intramuscularly, subcutaneously,
intracutaneously, percutaneously or intraperitoneally).
Administration forms suitable for parenteral administration are,
inter alia, preparations for injection and infusion in the form of
solutions, suspensions, emulsions, lyophilisates or sterile
powders.
Examples suitable for other administration routes are, for example,
pharmaceutical forms for inhalation (inter alia powder inhalers,
nebulizers), nasal drops/solutions/sprays; tablets to be
administered lingually, sublingually or buccally, films/wafers or
capsules, suppositories, preparations for the eyes or ears, vaginal
capsules, aqueous suspensions (lotions, shaking mixtures),
lipophilic suspensions, ointments, creams, transdermal therapeutic
systems, milk, pastes, foams, dusting powders, implants or
stents.
The compounds according to the invention can be converted into the
stated administration forms.
This can take place in a known manner with the mixing of inert,
non-toxic, pharmaceutically acceptable auxiliaries. These
auxiliaries include, inter alia, carriers (for example
microcrystalline cellulose, lactose, mannitol), solvents (for
example liquid polyethylene glycols), emulsifiers and dispersants
or wetting agents (for example sodium dodecyl sulphate,
polyoxysorbitan oleate), binders (for example
polyvinylpyrrolidone), synthetic and natural polymers (for example
albumin), stabilizers (for example antioxidants such as ascorbic
acid), colorants (for example inorganic pigments such as iron
oxides) and flavour- and/or odour-masking agents.
The present invention furthermore provides medicaments comprising
at least one compound according to the invention, usually together
with one or more inert, non-toxic, pharmaceutically acceptable
auxiliaries, and their use for the purposes mentioned above.
In general, it has proved advantageous to administer on intravenous
administration amounts of about 0.001 to 10 mg/kg, preferably about
0.01 to 5 mg/kg, of body weight to achieve effective results, and
the dosage on oral administration is about 0.01 to 25 mg/kg,
preferably 0.1 to 10 mg/kg, of body weight.
It may nevertheless be necessary where appropriate to deviate from
the amounts mentioned, specifically as a function of the body
weight, administration route, individual response to the active
compound, mode of preparation and time or interval over which
administration takes place. Thus, it may be sufficient in some
cases to make do with less than the aforementioned minimal amount,
whereas in other cases the upper limit mentioned must be exceeded.
It may in the event of administration of larger amounts be
advisable to divide these into a plurality of individual doses over
the day.
The percentage data in the following tests and examples are
percentages by weight unless otherwise indicated; parts or parts by
weight. Solvent ratios, dilution ratios and concentration data of
liquid/liquid solutions are in each case based on volume.
A. EXAMPLES
Abbreviations:
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl CDCl.sub.3
deuterated chloroform DCI direct chemical ionization (in MS) DCM
dichloromethane DIEA N,N-diisopropylethylamine DMSO dimethyl
sulphoxide DMF N,N-dimethylformamide EA ethyl acetate EI electron
impact ionization (in MS) ESI electrospray ionization (in MS) h
hour HPLC high-pressure, high-performance liquid chromatography
LC-MS liquid-chromatography-coupled mass spectroscopy LDA lithium
diisopropylamide min minutes m.p. melting point MS mass
spectroscopy MTBE methyl tert-butyl ether NMR nuclear magnetic
resonance spectroscopy Pd-C palladium-on-carbon RP-HPLC reverse
phase HPLC RT room temperature R.sub.t retention time (in HPLC) THF
tetrahydrofuran TLC Thin-layer chromatography. General LC-MS and
HPLC methods:
Method 1 (analytical HPLC): column: Kromasil C18 60 mm.times.2 mm;
temperature: 30.degree. C.; flow rate: 0.75 ml/min; mobile phase A:
0.005 M HClO.sub.4, mobile phase B: acetonitrile; gradient:
.fwdarw.0.5 min 98% A, .fwdarw.4.5 min 10% A, .fwdarw.6.5 min 10%
A.
Method 2 (preparative HPLC): column: GromSil C18, 250 mm.times.30
mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm;
mobile phase A: water, mobile phase B: acetonitrile; gradient: 10%
B (3 min)->90% B (31 min)->90% B (34 min)->10% B (34.01
min).
Method 3 (LC-MS): column: GromSil 120 ODS-4 HE, 50 mm.times.2.0 mm,
3 .mu.m; mobile phase A: 1 l of water+1 ml of 50% strength formic
acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength
formic acid; gradient: 0.0 min 100% A.fwdarw.0.2 min 100%
A.fwdarw.2.9 min 30% A.fwdarw.3.1 min 10% A.fwdarw.4.5 min 10% A;
oven: 55.degree. C.; flow rate: 0.8 ml/min; UV detection: 208-400
nm.
Method 4 (preparative HPLC, separation of enantiomers, carboxylic
acids): column: packing chiral silica gel selector KBD 8361 (420
mm.times.100 mm) based on the selector
.[.poly(N-methacryloyl-L-leucine-1-menthylamide).].
.Iadd.poly(N-methacryloyl-L-leucine-1-methylamide).Iaddend.;
temperature: 23.degree. C.; mobile phase: methyl tert-butyl ether;
flow rate: 100 ml/min; the compound is dissolved in methyl
tert-butyl ether/ethyl acetate (9:1).
Method 5 (preparative HPLC): column: GromSil C18, 250 mm.times.30
mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm;
mobile phase A: water with 0.1% formic acid, mobile phase B:
acetonitrile; gradient: 10% B (3 min)->90% B (31 min)->90% B
(34 min)->10% B (34.01 min).
Method 6 (analytical HPLC): instrument: HP 1100 with DAD detection;
column: Kromasil RP-18, 60 mm.times.2 mm, 3.5 .mu.m; mobile phase
A: 5 ml of HClO.sub.4/l of water, mobile phase B: acetonitrile;
gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B;
flow rate: 0.75 ml/min; temp.: 30.degree. C.; detection: UV 210
nm.
Method 7 (LC-MC): instrument: Micromass Platform LCZ with HPLC
Agilent series 1100; column: Grom-SIL 120 ODS-4 HE, 50 mm.times.2.0
mm, 3 .mu.m; mobile phase A: 1 l of water+1 ml of 50% strength
formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50%
strength formic acid; gradient: 0.0 min 100% A.fwdarw.0.2 min 100%
A.fwdarw.2.9 min 30% A.fwdarw.3.1 min 10% A.fwdarw.4.5 min 10% A;
oven: 55.degree. C.; flow rate: 0.8 ml/min; UV detection: 210
nm.
Method 8 (LC-MC): instrument: Micromass Platform LCZ, HP 1100;
column: Symmetry C18, 50 mm.times.2.1 mm, 3.5 .mu.m; mobile phase
A: acetonitrile+0.1% formic acid, mobile phase B: water+0.1% formic
acid; gradient: 0.0 min 10% A.fwdarw.4.0 min 90% A.fwdarw.6.0 min
90% A; oven: 40.degree. C.; flow rate: 0.5 ml/min; UV detection:
208-400 nm.
Method 9 (LC-MC): MS instrument: Micromass ZQ; HPLC instrument:
Waters Alliance 2795; column: Merck Chromolith SpeedROD RP-18e 50
mm.times.4.6 mm; mobile phase A: water+500 .mu.l of 50% strength
formic acid/l, mobile phase B: acetonitrile+500 .mu.l of 50%
strength formic acid/l; gradient: 0.0 min 10% B.fwdarw.3.0 min 95%
B.fwdarw.4.0 min 95% B; oven: 35.degree. C.; flow rate: 0.0 min 1.0
ml/min.fwdarw.3.0 min 3.0 ml/min.fwdarw.4.0 min 3.0 ml/min; UV
detection: 210 nm.
Method 10 (LC-MC): MS instrument: Micromass ZQ; HPLC instrument: HP
1100 Series; UV DAD; column: Grom-Sil 120 ODS-4 HE 50 mm.times.2
mm, 3.0 .mu.m; mobile phase A: water+500 .mu.l of 50% strength
formic acid/l, mobile phase B: acetonitrile+500 .mu.l of 50%
strength formic acid/l; gradient: 0.0 min 0% B.fwdarw.2.9 min 70%
B.fwdarw.3.1 min 90% B.fwdarw.4.5 min 90% B; oven: 50.degree. C.;
flow rate: 0.8 ml/min; .[.WV.]. .Iadd.UV .Iaddend.detection: 210
nm.
Method 11 (preparative HPLC, separation of enantiomers): column:
packing chiral silica gel selector KBD 8361 (250 mm.times.20 mm)
based on the selector
.[.poly(N-methacryloyl-L-leucine-1-menthylamide).].
.Iadd.poly(N-methacryloyl-L-leucine-1-methylamide).Iaddend.;
temperature: 23.degree. C.; mobile phase: methyl tert-butyl
ether+5% ethyl acetate; flow rate: 25 ml/min.
Method 12 (preparative HPLC, separation of enantiomers): column:
packing chiral silica gel selector KBD 5326 (250 mm.times.20 mm)
based on the selector
poly(N-methacryloyl-L-leucine-dicyclopropylmethylamide);
temperature: 23.degree. C.; mobile phase: methyl tert-butyl
ether+5% ethyl acetate; flow rate: 25 ml/min.
Method 13 (preparative HPLC, separation of enantiomers): column:
packing chiral silica gel selector KBD 8361 (250 mm.times.20 mm)
based on the selector
.[.poly(N-methacryloyl-L-leucine-1-menthylamide).].
.Iadd.poly(N-methacryloyl-L-leucine-1-methylamide).Iaddend.;
temperature: 23.degree. C.; mobile phase: methyl tert-butyl ether;
flow rate: 25 ml/min.
Method 14 (preparative HPLC, separation of enantiomers, esters):
column: packing chiral silica gel selector KBD 8361 (420
mm.times.100 mm) based on the selector
.[.poly(N-methacryloyl-L-leucine-1-menthylamide).].
.Iadd.poly(N-methacryloyl-L-leucine-1-methylamide).Iaddend.;
temperature: 23.degree. C.; mobile phase: isohexane/ethyl acetate
85/15 v/v; flow rate: 100 ml/min; the compound is dissolved in
isohexane/ethyl acetate (85:15).
Method 15 (preparative HPLC, separation of enantiomers, esters):
column: packing chiral silica gel selector KBD 8361 (420
mm.times.100 mm) based on the selector
.[.poly(N-methacryloyl-L-leucine-1-menthylamide).].
.Iadd.poly(N-methacryloyl-L-leucine-1-methylamide).Iaddend.;
temperature: 23.degree. C.; mobile phase: methyl tert-butyl ether;
flow rate: 100 ml/min; the compound is dissolved in methyl
tert-butyl ether.
Method 16 (LC-MS): instrument: Micromass Platform LCZ with HPLC
Agilent Series 1100; column: Grom-SIL120 ODS-4 HE, 50 mm.times.2.0
mm, 3 .mu.m; mobile phase A: 1 l of water+1 ml of 50% strength
formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50%
strength formic acid; gradient: 0.0 min 100% A.fwdarw.0.2 min 100%
A.fwdarw.2.9 min 30% A.fwdarw.3.1 min 10% A.fwdarw.4.5 min 10% A;
oven: 55.degree. C.; flow rate: 0.8 m/min; UV detection: 208-400
nm.
Method 17 (LC-MS): MS instrument: Micromass ZQ; HPLC instrument:
Waters Alliance 2790; column: Grom-Sil 120 ODS-4 HE 50 mm.times.2
mm, 3.0 .mu.m; mobile phase A: water+500 .mu.l of 50% strength
formic acid/l, mobile phase B: acetonitrile+500 .mu.l of 50%
strength formic acid/l; gradient: 0.0 min 0% B.fwdarw.0.2 min 0%
B.fwdarw.2.9 min 70% B.fwdarw.3.1 min 90% B.fwdarw.4.5 min 90% B;
oven: 45.degree. C.; flow rate: 0.8 ml/min; UV detection: 210
nm.
Starting Materials
General Procedure [A]: Synthesis of Substituted 2-aminocinnamic
Acid Derivatives by Heck Coupling from 2-halo-substituted
Anilines
In a one-necked flask, 1.0 equivalent of an aryl halide is
initially charged with 1.6 equivalents of methyl acrylate or
tert-butyl acrylate, 2.0 equivalents of triethylamine, 0.03
equivalents of palladium(II) acetate and 0.03 equivalents of
.[.trio-tolylphosphine.]. .Iadd.tri-o-tolylphosphine .Iaddend.in
acetonitrile (solution about 1M). The mixture is stirred under
reflux for 48 hours. After the reaction has ended (the reaction is
monitored by TLC), the solvent is removed. The residue is purified
chromatographically on silica gel using cyclohexane/ethyl
acetate=8:2 v/v.
Example 1A
Methyl (2E)-3-[2-amino-3-fluorophenyl]propenoate
##STR00012##
Starting with 42.00 g (221.04 mmol) of 2-bromo-6-fluoroaniline, the
general procedure [A] gives 29.66 g (68% of theory) of product.
HPLC (Method 1): R.sub.t=4.14 min
MS (ESI-pos): m/z=196 (M+H).sup.+
Example 2A
Methyl 2-amino-3-[(1E)-3-methoxy-3-oxo-1-propenyl]benzoate
##STR00013##
Starting with 2.00 g (8.69 mmol) of methyl 2-amino-3-bromobenzoate,
the general procedure [A] gives 1.29 g (60% of theory) of
product.
HPLC (Method 1): R.sub.t=4.42 min
MS (ESI-pos): m/z=236 (M+H).sup.+
Example 3A
Methyl (2E)-3-(2-amino-3,5-difluorophenyl)-2-propenoate
##STR00014##
Starting with 3.00 g (14.42 mmol) of 2-bromo-4,6-difluoroaniline,
the general procedure [A] gives 1.41 g (45% of theory) of
product.
HPLC (Method 1): R.sub.t=4.23 min
MS (ESI-pos): m/z=214 (M+H).sup.+
Example 4A
Methyl 4-amino-3-[(1E)-3-methoxy-3-oxo-1-propenyl]benzoate
##STR00015##
Starting with 25.00 g (90.23 mmol) of methyl
4-amino-3-iodobenzoate, the general procedure [A] gives 24.31 g
(92% of theory) of product.
HPLC (Method 1): R.sub.t=4.71 min
MS (ESI-pos): m/z=278 (M+H).sup.+
Example 5A
Methyl (2E)-3-[2-amino-5-cyanophenyl]-2-propenoate
##STR00016##
Starting with 1.90 g (9.64 mmol) of 3-bromo-4-aminobenzonitrile,
the general procedure [A] gives 1.28 g (50% of theory) of
product.
HPLC (Method 1): R.sub.t=2.85 min
MS (DCI-pos): m/z=220 (M+NH.sub.4).sup.+
General Procedure [B]: Synthesis of substituted 2-nitrocinnamic
acid derivatives by Wittig-Horner reaction from 2-halo-substituted
benzaldehydes
In a 100 ml one-necked flask, 27.5 mmol of methyl diethyl
phosphonoacetate, 25.0 mmol of the benzaldehyde and 27.5 mmol of
lithium hydroxide are suspended in tetrahydrofuran. After the
reaction has ended (the reaction is monitored by TLC), the reaction
mixture is mixed with the same volume of water. The aqueous phase
is extracted three times with ethyl acetate. The combined organic
phases are washed with saturated sodium chloride solution and dried
over sodium sulphate, and the solvent is removed. The product is
dried under high vacuum at RT, without further purification. If the
product is very impure, it is, if appropriate, purified by column
chromatography on silica gel using cyclohexane/ethyl acetate.
Example 6A
Methyl (2E)-3-(3-methoxy-2-nitrophenyl)-2-propenoate
##STR00017##
Starting with 2.00 g (11.04 mmol) of 3-methoxy-2-nitrobenzaldehyde,
the general procedure [B] gives 2.46 g (92% of theory) of
product.
HPLC (Method 1): R.sub.t=4.37 min
MS (ESI-pos): m/z=238 (M+H).sup.+
Example 7A
Methyl (2E)-3-(5-fluoro-2-nitrophenyl)-2-propenoate
##STR00018##
Starting with 20.0 g (118.3 mmol) of 5-fluoro-2-nitrobenzaldehyde,
the general procedure [B] gives 7.25 g (27% of theory) of
product.
MS (DCI): m/z=243 (M+NH.sub.4).sup.+
General Procedure [C]: Preparation of a 2-nitrobenzaldehyde from a
Benzyl Halide
10.0 mmol of the benzyl halide, 4.1 g of molecular sieve 4 .ANG.
and 20.0 mmol of N-methylmorpholine N-oxide are suspended in 45 ml
of acetonitrile. The mixture is stirred at RT until the reaction
has gone to completion (the reaction is monitored by TLC). After
the reaction has ended, the molecular sieve is filtered off, the
solvent is removed and the residue is taken up again in ethyl
acetate. This solution is initially washed with 1N hydrochloric
acid and then with saturated sodium chloride solution. The organic
phase is separated off and then dried over sodium sulphate, and the
solvent is again removed. Analysis shows that the crude product is
sufficiently pure and can directly be reacted further.
Example 8A
2-Fluoro-6-nitrobenzaldehyde
##STR00019##
Starting with 2.00 g (8.55 mmol) of 3-fluoro-6-nitrobenzyl bromide,
the general procedure [C] gives 1.09 g (75% of theory) of
product.
HPLC (Method 1): R.sub.t=3.58 min
General Procedure [D]: Reduction of the Nitro Group of the
2-nitrocinnamic Acid Derivatives
Under argon, 25 mmol of the nitro compound and 125 mmol of tin(II)
chloride dihydrate are initially charged in 60 ml of absolute
ethanol in a 250 ml two-necked flask. This suspension is stirred
under reflux for 30 minutes, and a clear solution is formed. The
solution is then cooled to room temperature and subsequently poured
onto ice-water. Using either solid sodium bicarbonate or a
saturated sodium carbonate solution, the pH is adjusted to pH=7-8.
60 ml of ethyl acetate are then added, and the precipitated tin
salts are filtered off through kieselguhr (a layer of a thickness
of about 1 cm). The organic phase is separated off and the aqueous
phase is re-extracted with ethyl acetate. The organic phases are
combined, washed once with saturated sodium chloride solution and
dried over sodium sulphate, and the solvent is concentrated to
about half of its original volume. Activated carbon corresponding
to 1% of the weight of the nitro compound is then added, and the
mixture is heated under reflux for 30 minutes (the colour of the
solution changes). The activated carbon is filtered off and the
solvent is removed.
The residue obtained is an oil which, on drying at RT under high
vacuum, forms crystals. Without further purification, the product
is directly used for the next step.
Example 9A
Methyl 3-[2-amino-6-fluorophenyl]propenoate
##STR00020##
Starting with 7.25 g (32.2 mmol) of the nitro compound from Example
7A, the general procedure [D] gives 5.0 g (58% of theory) of
product.
HPLC (Method 1): R.sub.t=3.33 min
General Procedure [E]: Synthesis of the Iminophosphoranes by Appel
Reaction of the Substituted Anilines
In a 50 ml one-necked flask, 10.0 mmol of the amine of the
2-aminocinnamic ester, 20.0 mmol of triphenylphosphine, 100.0 mmol
of carbon tetrachloride and 100.0 mmol of triethylamine are
dissolved in 20 ml of acetonitrile. The mixture is stirred at room
temperature for 2 hours. After the reaction has ended (the reaction
is monitored by TLC or analytic HPLC), the solvent is removed under
reduced pressure and the residue is purified by column
chromatography on silica gel using cyclohexane/ethyl
acetate=7:3.
Example 10A
Methyl
(2E)-3-{3-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}prope-
noate
##STR00021##
Starting with 29.3 g (150.1 mmol) of the amine compound from
Example 1A, the general procedure [E] gives 55.0 g (80% of theory)
of product.
HPLC (Method 1): R.sub.t=4.46 min
MS (ESI-pos): m/z=456 (M+H).sup.+
Example 11A
Methyl
(2E)-3-{5-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}prope-
noate
##STR00022##
Starting with 50.0 g (256.2 mmol) of the amine compound from
Example 9A, the general procedure [E] gives 89.6 g (77% of theory)
of product.
HPLC (Method 1): R.sub.t=4.36 min
MS (ESI-pos): m/z=456 (M+H).sup.+
Example 12A
Methyl
(2E)-3-{5-cyano-2-[(triphenylphosphoranylidene)amino]phenyl}propen-
oate
##STR00023##
Starting with 1.24 g (4.60 mmol) of the amine compound from Example
5A, the general procedure
[E] gives 2.12 g (92% of theory) of product.
HPLC (Method 1): R.sub.t=4.42 min
MS (ESI-pos): m/z=463 (M+H).sup.+
General Procedure [F]: Synthesis of Phenylpiperazines by the
Buchwald-Hartwig Reaction
To prepare for the reaction, the reaction flask is thoroughly dried
by heating under high vacuum and vented with argon. 1.0 equivalent
of the bromoaryl compound and 6.0 equivalents of piperazine in
absolute toluene are initially charged in the flask (0.2-0.3M
solution of the bromo compound). 0.01 equivalent of
tris(dibenzylideneacetone)dipalladium and 0.03 equivalent of BINAP
are then added. The reaction mixture is stirred under reflux for 16
h. The mixture is then extracted once with water, the organic phase
is extracted twice with 1N hydrochloric acid and the aqueous phase
is adjusted to pH 8 using 1N aqueous sodium hydroxide solution and
extracted three times with dichloromethane. The combined organic
phases are dried over sodium sulphate and filtered, the solvent is
removed under reduced pressure and the product is dried under high
vacuum overnight.
Example 13A
N-(4-Fluoro-3-methylphenyl)piperazine
##STR00024##
Starting with 5.0 g (26.5 mmol) of
4-fluoro-3-methyl-1-bromobenzene, the general procedure [F] gives
4.52 g (83% of theory) of product.
HPLC (Method 1): R.sub.t=3.54 min
MS (ESI pos): m/z=195 (M+H).sup.+
Example 14A
N-(4-Fluorophenyl)-3-methylpiperazine
##STR00025##
Starting with 1.0 g (5.71 mmol) of
4-fluoro-3-methyl-1-bromobenzene, the general procedure [F] gives
0.57 g (49% of theory) of product.
HPLC (Method 1): R.sub.t=3.37 min
MS (DCI pos): m/z=195 (M+H).sup.+
Example 15A
1-(3-Fluorophenyl)piperazine
##STR00026##
1 g (5.71 mmol) of 3-fluorobromobenzene and 2.95 g (34.29 mmol) of
piperazine are dissolved in 20 ml of toluene, and 0.77 g (8 mmol)
of sodium tert-butoxide is added. In the presence of 0.11 g (0.17
mmol) of BINAP and 0.05 g (0.06 mmol) of
tris(dibenzylideneacetone)dipalladium, the mixture is then stirred
under reflux overnight. After cooling, ethyl acetate is added and
the mixture is washed with water. The mixture is then extracted
with 1N hydrochloric acid, and the aqueous phase is washed with
ethyl acetate. The pH is adjusted to 8-9 and the mixture is then
extracted with dichloromethane. The organic phase is dried over
magnesium sulphate and the solvent is removed, giving the target
compound.
Yield: 0.8 g (78% of theory)
HPLC (Method 1): R.sub.t=3.4 min
MS (ESI-pos): m/z=181 (M+H).sup.+
Example 16A
1-(3,4-Difluorophenyl)piperazine
##STR00027##
In 100 ml of toluene, 5 g (25.91 mmol) of 3,4-difluorobromobenzene,
13.39 g (155.45 mmol) of piperazine, 3.49 g (36.27 mmol) of sodium
tert-butoxide, 0.24 g (0.26 mmol) of
tris(dibenzylidene-acetone)dipalladium and 0.48 g (0.78 mmol) of
BINAP are stirred under reflux overnight. Ethyl acetate is added,
the mixture is then washed with water and the organic phase is
extracted with 1N hydrochloric acid. The aqueous phase is then
washed with ethyl acetate and subsequently adjusted to pH 8. Using
dichloromethane, the product is extracted from the aqueous phase.
The extract is then dried over magnesium sulphate, the solvent is
removed and the target compound is dried under reduced
pressure.
Yield: 3.85 g (75% of theory)
HPLC (Method 1): R.sub.t=3.4 min
MS (DCI): m/z=199 (M+H).sup.+
Example 17A
2-Isocyanato-1-methoxy-4-(trifluoromethyl)benzene
##STR00028##
3 g (15.69 mmol) of 2-methoxy-5-trifluoromethylaniline are
dissolved in 100 ml of dichloromethane, and 6.73 g (31.39 mmol) of
1,8-bis(dimethylamino)naphthalene are added. At 0-5.degree. C.,
2.24 g (11.3 mmol) of trichloromethyl chloroformate, dissolved in
50 ml of dichloromethane, are added dropwise, and the mixture is
stirred at 0.degree. C. for 30 min and then at room temperature for
60 min. At 0.degree. C., the mixture is washed with 1N hydrochloric
acid, ice-water and sodium bicarbonate solution. Drying over
magnesium sulphate and removal of the solvent by distillation gives
the product. The isocyanate is then used for the subsequent
reactions without further purification.
Yield: 3.00 g (88% of theory)
Example 18A
Methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]imino}m-
ethylene)amino]-phenyl}-2-propenoate
##STR00029##
5.0 g (10.98 mmol) of methyl
(2E)-3-{3-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}-2-propenoat-
e (Example 10A) are initially charged in 50 ml of dichloromethane,
and the mixture is stirred with 2.5 g (11.53 mmol) of
2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene (Example 17A) at
room temperature overnight. The solvent is removed by distillation
and the product is then purified by chromatography on silica gel
(isohexane/dichloromethane 2:1; 1:1) and recrystallized from
isohexane.
Yield: 2.69 g (62% of theory)
HPLC (Method 1): R.sub.t=5.6 min
MS (ESI-pos): m/z=395 (M+H).sup.+
General Procedure [G]: Reaction of the Iminophosphorane with an
Isocyanate and Subsequent Reaction with an Amine to Give the
Dihydroquinazoline Derivative
1.0 equivalent of the iminophosphorane is dissolved in 20 ml of
dichloromethane (0.1-0.2M solution). 1.05 equivalents of a
substituted isocyanate are then added, and the mixture is stirred
at RT until the reaction has ended. The reaction is monitored by
TLC or by analytical HPLC.
1.0 equivalent of amine and a spatula tip of silica gel are then
added to the resulting solution of the carbodiimide and
dichloromethane, and the mixture is stirred at room temperature
until the reaction has gone to completion. After the reaction has
ended (reaction is monitored by TLC or HPLC), the mixture is
concentrated and purified by preparative HPLC on an RP phase.
In certain cases, the NMR shows the presence of a varying
proportion of non-cyclized reaction product. In those cases, the
mixture of cyclized and non-cyclized product is taken up in
dioxane, a spatula tip of silica gel is added and the mixture is
stirred under reflux for 30 min to 16 h. The silica gel is filtered
off and the solution is used for further reactions.
If it is intended to produce enantiomerically pure compounds, the
chromatographic separation is carried out at this stage.
Example 19A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00030##
Starting with 92.5 mg (0.2 mmol) of the iminophosphorane from
Example 10A, the general procedure [G] gives 50 mg (45% of theory)
of product.
HPLC (Method 1): R.sub.t=4.81 min
Example 20A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00031##
This compound is obtained as enantiomer A following the separation
of enantiomers of 3.84 g of Example 19A (715 mg, 14% of
theory).
HPLC (Method 1): R.sub.t=4.81 min
MS (ESI-pos): m/z=544.9 (M+H).sup.+
Example 21A
Methyl
{6-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00032##
Starting with 100 mg (0.28 mmol) of the iminophosphorane from
Example .[.1A.]. .Iadd.11A.Iaddend., the general procedure [G]
gives 58 mg (39% of theory) of product.
HPLC (Method 1): R.sub.t=4.80 min
Example 22A
Methyl
{6-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00033##
This compound is obtained as enantiomer A following the separation
of enantiomers of 832 mg of Example 21A (368 mg, 17% of
theory).
HPLC (Method 1): R.sub.t=4.77 min
MS (ESI-pos): m/z=544.9 (M+H).sup.+
Example 23A
Methyl
{8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00034##
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example
10A, the general procedure [G] gives 43 mg (39% of theory) of
product.
HPLC (Method 1): R.sub.t=4.80 min
MS (ESI-pos): m/z=541.0 (M+H).sup.+
Example 24A
Methyl
{8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00035##
This compound is obtained as enantiomer A following the separation
of enantiomers of 3.31 g of Example 23A (1.18 g, 22% of
theory).
HPLC (Method 1): R.sub.t=4.80 min
MS (ESI-pos): m/z=541.0 (M+H).sup.+
Example 25A
Methyl
{8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromet-
hyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00036##
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example
10A, the general procedure [G] gives 51 mg (45% of theory) of
product.
HPLC (Method 1): R.sub.t=4.62 min
MS (ESI-pos): m/z=556.7 (M+H).sup.+
Example 26A
Methyl
{8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromet-
hyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00037##
This compound is obtained as enantiomer A following the separation
of enantiomers of 5.11 g of Example 25A (0.49 g, 9% of theory).
HPLC (Method 1): R.sub.t=4.71 min
MS (ESI-pos): m/z=556.8 (M+H).sup.+
Example 27A
Methyl
{8-fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-metho-
xy-3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00038##
Starting with 1.0 g (2.2 mmol) of the iminophosphorane from Example
10A, 500 mg (2.31 mmol) of
2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene (Example 17A) and
427 mg (2.2 mmol) of the phenylpiperazine from Example 13A, 1.03 g
(79% of theory) of crude product are obtained following filtration
through silica gel (cyclohexane/ethyl acetate 2:1 (v/v)). This
product is reacted further without further purification.
LC-MS (Method 3): R.sub.t=2.55 min, 2.66 min
MS (ESI-pos): m/z=589.3 (M+H).sup.+
Example 28A
Methyl
{8-fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-metho-
xy-3-methylphenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00039##
Starting with 0.60 g (1.76 mmol) of the iminophosphorane from
Example 10A, 376 mg (2.31 mmol) of 2-methoxy-5-methylphenyl
isocyanate and 342 mg (1.76 mmol) of the phenylpiperazine from
Example 13A, 183 mg (16% of theory) of product are obtained after
purification by preparative HPLC.
HPLC (Method 1): R.sub.t=4.77 min
MS (ESI-pos): m/z=535.2 (M+H).sup.+
Example 29A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chlo-
rophenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00040##
Starting with 1.0 g (2.2 mmol) of the iminophosphorane from Example
10A, 423 mg (2.31 mmol) of 2-methoxy-5-chlorophenyl isocyanate and
396 mg (2.2 mmol) of 4-fluorophenylpiperazine, 621 mg (52% of
theory) of product are obtained after purification by preparative
HPLC.
HPLC (Method 1): R.sub.t=4.75 min
MS (ESI-pos): m/z=541.2 (M+H).sup.+
Example 30A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(tri-
fluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00041##
550 mg (1.39 mmol) of methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methyle-
ne)amino]phenyl}-2-propenoate (Example 18A) and 251 mg (1.39 mmol)
of 1-(4-fluorophenyl)piperazine are stirred in the presence of a
spatula tip of silica gel in 15 ml of dichloromethane for 1 hour.
After 90 hours of stirring under reflux, the product is purified by
chromatography on silica gel (dichloromethane,
dichloromethane/ethyl acetate 10:1).
Yield: 769 mg (96% of theory)
HPLC (Method 1): R.sub.t=4.8 min
MS (ESI-pos): m/z=575 (M+H).sup.+
Example 31A
Methyl
{8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(tr-
ifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00042##
700 mg (1.78 mmol) of methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methyle-
ne) amino]phenyl}-2-propenoate (Example 18A), 341 mg (1.78 mmol) of
1-(3-methoxyphenyl)piperazine and a spatula tip of silica gel are
stirred in 20 ml of dichloromethane at room temperature for one
hour and then under reflux for 35 hours. The target compound is
obtained after purification on silica gel (dichloromethane,
dichloromethane/ethyl acetate 10:1).
Yield: 1012 mg (97% of theory)
HPLC (Method 6): R.sub.t=4.8 min
MS (ESI-pos): m/z=587 (M+H).sup.+
Example 32A
Methyl
{8-fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5--
(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00043## 700 mg (1.78 mmol) of methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methyle-
ne)amino]phenyl}-2-propenoate (Example 18A), 352 mg (1.78 mmol) of
1-(3,4-difluorophenyl)piperazine (Example 16A) and a spatula tip of
silica gel are stirred in 20 ml of dichloromethane at room
temperature for 1 hour and then under reflux for 20 hours. The
target compound is then purified by chromatography on silica gel
(dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 1027 mg (97% of theory)
HPLC (Method 1): R.sub.t=4.8 min
MS (ESI-pos): m/z=593 (M+H).sup.+
Example 33A
Methyl
{8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(tri-
fluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00044##
11.5 g (29.16 mmol) of methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methyle-
ne)amino]phenyl}-2-propenoate (Example 18A), 5.14 g (29.16 mmol) of
1-(3-methylphenyl)piperazine and a spatula tip of silica gel are
stirred in 300 ml of dichloromethane at room temperature for 1 hour
and then under reflux for 20 hours. The product is obtained after
chromatography on silica gel (dichloromethane,
dichloromethane/ethyl acetate 10:1, 5:1).
Yield: 15.8 g (95% of theory)
HPLC (Method 1): R.sub.t=4.8 min
MS (ESI-pos): m/z=571 (M+H).sup.+
Example 34A
Methyl
{8-fluoro-2[-4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(tri-
fluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00045##
100 mg (0.25 mmol) of methyl
(2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methyle-
ne)amino]phenyl}-2-propenoate (Example 18A), 45.7 mg (0.25 mmol) of
1-(3-fluorophenyl)piperazine (Example 15A) and a spatula tip of
silica gel are stirred in 15 ml of dichloromethane at room
temperature for 1 hour and then under reflux for 20 hours. The
target compound is obtained after chromatography on silica gel
(dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 139.2 mg (96% of theory)
HPLC (Method 1): R.sub.t=4.8 min
MS (ESI-pos): m/z=575 .[.(M).sup.+.].
.Iadd.(M+H).sup.+.Iaddend.
Example 35A
Methyl
{8-fluoro-2-[4-(3-chlorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00046##
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example
10A, the general procedure [G] gives 51 mg (45% of theory) of
product.
LC-MS (Method 3): R.sub.t=4.78 min
MS (ESI-pos): m/z=561 (M+H).sup.+
Example 36A
Methyl
{8-fluoro-2-[4-(1,3-benzodioxol-5-yl)-1-piperazinyl]-3-[3-(trifluo-
romethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00047##
Starting with 4.19 g (9.2 mmol) of the iminophosphorane from
Example 10A, the general procedure [G] gives 3.67 g (70% of theory)
of product.
HPLC (Method 1): R.sub.t=4.67 min
MS (ESI-pos): m/z=571 (M+H).sup.+
Example 37A
Methyl
4-amino-3-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]benzoate
##STR00048##
Starting with 25.0 g (90.2 mmol) of methyl 4-amino-3-iodobenzoate,
the general procedure [A] gives 24.3 g (88% of theory) of
product.
HPLC (Method 1): R.sub.t=4.71 min
MS (DCI-pos): m/z=295 (M+NH.sub.4).sup.+
Example 38A
Methyl (2E)-3-(4-cyano-2-nitrophenyl)-2-propenoate
##STR00049##
Starting with 3.00 g (17.0 mmol) of 4-cyano-2-nitrobenzaldehyde,
the general procedure [B] and recrystallization from methanol gives
2.51 g (63% of theory) of product.
HPLC (Method 1): R.sub.t=4.06 min
MS (ESI-pos): m/z=233 (M+H).sup.+
Example 39A
Methyl 3-[2-amino-7-cyanophenyl]propenoate
##STR00050##
Starting with 1.0 g (4.31 mmol) of the nitro compound from Example
38A, the general procedure [D] (but without boiling over activated
carbon) gives 793 mg (89% of theory) of product.
HPLC (Method 1): R.sub.t=3.99 min
Example 40A
Methyl
(2E)-3-{6-cyano-2-[(triphenylphosphoranylidene)amino]phenyl}propen-
oate
##STR00051##
Starting with 0.75 g (3.71 mmol) of the amine compound from Example
39A, the general procedure [E] gives 1.09 g (62% of theory) of
product.
HPLC (Method 1): R.sub.t=4.30 min
MS (ESI-pos): m/z=463 (M+H).sup.+
Example 41A
Methyl
3-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]-4-[(triphenylphosphoran-
ylidene)amino]-benzoate
##STR00052##
Starting with 19.0 g (68.5 mmol) of the amine compound from Example
37A, the general procedure [E] gives 31.4 g (85% of theory) of
product.
HPLC (Method 1): R.sub.t=4.69 min
MS (ESI-pos): m/z=538 (M+H).sup.+
Example 42A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(tri-
fluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00053##
This compound is obtained as enantiomer A by separating the
racemate from Example 30A chromatographically according to Method
15 .[.in to.]. .Iadd.into .Iaddend.the enantiomers. Starting with
231 g of racemate, 120 g of the target product, which is directly
reacted further, are obtained.
MS (ESI-pos): m/z=575 (M+H).sup.+
Example 43A
Methyl
{8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(tr-
ifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00054##
The compound is obtained as enantiomer A by separating the racemate
from Example 31A chromatographically according to Method 15 into
the enantiomers. Starting with 231 g of racemate, 111 g (48% of
theory) of the target product are obtained.
MS (ESI-pos): m/z=587 (M+H).sup.+
Example 44A
Methyl
{6-cyano-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethy-
l)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00055##
Starting with 400 mg (0.6 mmol) of the iminophosphorane from
Example 12A, the general procedure [G] gives 166 mg (48% of theory)
of product.
HPLC (Method 1): R.sub.t=4.65 min
MS (ESI-pos): m/z=552 (M+H).sup.+
Example 45A
Methyl
{7-cyano-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethy-
l)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00056##
Starting with 1.0 g (2.16 mmol) of the iminophosphorane from
Example 40A, the general procedure [G] gives 1.07 g (98% of theory)
of product.
HPLC (Method 1): R.sub.t=4.72 min
MS (ESI-pos): m/z=552 (M+H).sup.+
Example 46A
Methyl
4-(2-tert-butoxy-2-oxoethyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]--
3-[3-(trifluoromethyl)-phenyl]-3,4-dihydroquinazoline-6-carboxylate
##STR00057##
Starting with 4.2 g (9.3 mmol) of the iminophosphorane from Example
41A, the general procedure [G] gives 3.9 g (51% of theory) of
product.
HPLC (Method 1): R.sub.t=5.03 min
MS (ESI-pos): m/z=627 (M+H).sup.+
Example 47A
Methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluorometh-
yl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
##STR00058##
This compound is obtained as enantiomer A following the separation
of enantiomers of 3.5 g of Example 46A (1.4 mg, 20% of theory).
HPLC (Method 1): R.sub.t=4.91 min
MS (ESI-pos): m/z=627 (M+H).sup.+
Example 48A
4-(2-tert-Butoxy-2-oxoethyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(t-
rifluoromethyl)phenyl]-3,4-dihydroquinazoline-6-carboxylic acid
##STR00059##
1.3 g (2.0 mmol) of the methyl carboxylate from Example 47A are
dissolved in 12 ml of dioxane, 2.4 ml of an aqueous 1N solution of
potassium hydroxide are added and the mixture is stirred at
60.degree. C. for 5 hours. The pH is adjusted to pH=4 using an
aqueous 1N solution of hydrochloric acid and the reaction mixture
is concentrated and purified by preparative HPLC. This gives 580 mg
(48% of theory) of the product.
HPLC (Method 1): R.sub.t=4.85 min
MS (ESI-pos): m/z=613 (M+H).sup.+
Example 49A
Tert-butyl
{6-(aminocarbonyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluorome-
thyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetate
##STR00060##
560 mg (0.9 mmol) of the carboxylic acid from Example 48A, 2.6 mmol
of aluminium chloride, 1.1 mmol of 1-hydroxy-1H-benzotriazole
hydrate and 1.1 mmol of
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide are suspended in
DMF. 2.6 mmol of N,N-diisopropylamine are added, and the mixture is
stirred at room temperature for 16 hours. 20 ml of ethyl acetate
are added to the reaction mixture, which is then washed with a
saturated aqueous sodium bicarbonate solution and a saturated
aqueous sodium chloride solution. The combined aqueous phases are
adjusted to pH=8 and extracted with ethyl acetate. The combined
organic phases are finally washed with a saturated aqueous sodium
chloride solution, dried over sodium sulphate and concentrated.
This gives 548 mg (97% of theory) of product.
HPLC (Method 1): R.sub.t=4.73 min
MS (ESI-pos): m/z=612 (M+H).sup.+
Examples 50A to .[.112A.]. .Iadd.111A .Iaddend.of Table 1 can be
prepared from the corresponding starting materials using the
general procedures [A] to [G].
TABLE-US-00001 TABLE 1 Example R.sub.4 HPLC MS ESIpos. No.
Structure [min] method [M + H].sup.+ 50A ##STR00061## 4.53 1 561 [M
+ H - HCl].sup.+ 51A ##STR00062## 4.22 1 556 [M + H - HCl].sup.+
52A ##STR00063## 4.36 1 552 [M + H - HCl].sup.+ 53A ##STR00064##
4.37 1 572 [M + H - HCl].sup.+ 54A ##STR00065## 4.54 1 549 [M + H -
HCl].sup.+ 55A ##STR00066## 4.27 1 568 [M + H - HCl].sup.+ 56A
##STR00067## 4.30 1 538 57A ##STR00068## 4.28 1 518 58A
##STR00069## 4.41 1 538 59A ##STR00070## 4.82 1 557 60A
##STR00071## 4.61 1 549 [M + H - HCl].sup.+ 61A ##STR00072## 4.89 1
517 62A ##STR00073## 4.81 6 605 63A ##STR00074## 4.60 6 591 64A
##STR00075## 4.85 6 591 65A ##STR00076## 4.92 6 609 66A
##STR00077## 4.83 1 603 67A ##STR00078## 4.78 1 587 68A
##STR00079## 5.13 1 563 69A ##STR00080## 4.76 1 563 70A
##STR00081## 4.81 1 581 71A ##STR00082## 5.21 1 581 72A
##STR00083## 5.21 1 575 73A ##STR00084## 4.98 1 559 74A
##STR00085## 4.86 1 591 75A ##STR00086## 4.86 6 593 76A
##STR00087## 4.94 1 547 77A ##STR00088## 4.82 1 539 78A
##STR00089## 4.92 1 589 79A ##STR00090## 4.57 1 582 80A
##STR00091## 2.38 3 495 81A ##STR00092## 1.95 9 491 82A
##STR00093## 1.97 9 507 83A ##STR00094## 1.93 9 511 84A
##STR00095## 1.90 9 487 85A ##STR00096## 4.87 1 541 86A
##STR00097## 4.91 1 561 87A ##STR00098## 4.76 1 557 88A
##STR00099## 4.65 1 552 89A ##STR00100## 4.77 1 568 90A
##STR00101## 4.62 1 564 91A ##STR00102## 5.00 1 609 92A
##STR00103## 4.70 1 563 93A ##STR00104## 577 94A ##STR00105## 4.74
1 545 95A ##STR00106## 4.90 1 605 96A ##STR00107## 4.83 1 563 97A
##STR00108## 4.82 1 537 98A ##STR00109## 4.90 1 557 99A
##STR00110## 4.81 1 553 100A ##STR00111## 101A ##STR00112## 4.78 1
521 102A ##STR00113## 4.73 1 517 103A ##STR00114## 3.10 16 533 104A
##STR00115## 2.75 17 555 105A ##STR00116## 2.95 17 555 106A
##STR00117## 4.74 1 545 107A ##STR00118## 4.93 1 541 108A
##STR00119## 5.08 1 575 109A ##STR00120## 4.88 1 563 110A
##STR00121## 4.54 1 531 [M + H - HCl].sup.+ 111A ##STR00122## 4.54
1 571 [M + H - HCl].sup.+
WORKING EXAMPLES
General Procedure [H]: Hydrolysis of the Quinazolylacetic Acid
Esters
1.0 equivalent of the quinazolyl ester are dissolved in dioxane,
and 5.0 equivalents of 1N aqueous sodium hydroxide solution are
added. The mixture is stirred at 80.degree. C. for 16 hours, and
after the reaction has ended (the reaction is monitored by
analytical HPLC) the mixture is concentrated. The residue is then
taken up in water and adjusted to pH 5 using 1N hydrochloric acid.
The resulting precipitate is filtered off, washed with a little
water and diethyl ether and dried at room temperature under high
vacuum. Alternatively, the precipitate can be filtered off through
an Extrelute cartridge, then washed with ethyl acetate, followed by
concentration of the filtrate. If the purity of the product is not
high enough, the product is purified either by preparative HPLC on
an RP phase (Method 2 or Method 5) or on silica gel using mixtures
of cyclohexane/ethyl acetate.
Example 1
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00123##
Starting with 37 mg (0.07 mmol) of the methyl ester from Example
19A, the general procedure [H] gives 29 mg (80% of theory) of
product.
HPLC (Method 1): R.sub.t=4.49 min
MS (ESI-pos): m/z=530.7 (M+H).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.59 (s, 1H); 7.45
(t, 1H); 7.37 (t, 2H); 7.02-6.95 (m, 3H); 6.93-6.85 (m, 4H); 5.24
(dd, 1H); 2.98 (d.sub.b, 4H); 2.91 (d.sub.b, 4H); 2.73 (dd, 1H);
2.54 (dd, 1H).
Example 2
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00124##
Starting with 695 mg (1.27 mmol) of the methyl ester from Example
20A, the general procedure [H] gives 488 mg (64% of theory) of
product.
HPLC (Method 1): R.sub.t=4.59 min
MS (ESI-pos): m/z=530.8 (M+H).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.60 (s, 1H);
7.47-7.40 (m, 3H); 7.03-6.86 (m, 7H); 5.26-5.23 (m, 1H); 3.60-3.52
(m, 4H); 2.99-2.90 (m, 4H); 2.75 (dd, 1H); 2.56 (dd, 1H).
Example 3
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00125##
Starting with 34 mg (0.06 mmol) of the methyl ester from Example
23A, the general procedure [H] gives 30 mg (90% of theory) of
product.
HPLC (Method 1): R.sub.t=4.56 min
MS (ESI-pos): m/z=526.9 (M+H).sup.+
.sup.1H NMR (200 MHz, DMSO-d.sub.6): .delta. [ppm]=7.64 (s, 1H);
7.53 (t, 1H); 7.44-7.34 (m, 2H); 7.11-6.90 (m, 3H); 6.72-6.59 (m,
4H); 5.33-5.25 (m, 1H); 3.52 (d.sub.b, 4H); 3.02 (d.sub.b, 4H);
2.69-2.55 (m, 2H, partially obscured by DMSO signal); 2.23 (s,
3H).
Example 4
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phe-
nyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00126##
Starting with 36 mg (0.07 mmol) of the methyl ester from Example
25A, the general procedure [H] and chromatography (Method 2) give
28 mg (77% of theory) of product.
HPLC (Method 1): R.sub.t=4.46 min
MS (ESI-pos): m/z=542.9 (M+H).sup.+
.sup.1H NMR (200 MHz, DMSO-d.sub.6): .delta. [ppm]=7.67 (s, 1H);
7.54 (t, 1H); 7.45-7.38 (m, 2H); 7.14-6.94 (m, 3H); 6.51-6.35 (m,
4H); 5.35-5.25 (m, 1H); 3.69 (s, 3H); 3.50 (d.sub.b, 4H); 3.06
(d.sub.b, 4H); 2.58-2.52 (m, 2H).
Example 5
{8-Fluoro-2-[4-(3-chlorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00127##
Starting with 38 mg (0.07 mmol) of the methyl ester from Example
35A, the general procedure [H] gives 25 mg (66% of theory) of
product.
HPLC (Method 1): R.sub.t=4.64 min
MS (ESI-pos): m/z=546.9 (M+H).sup.+
.sup.1H NMR (200 MHz, DMSO .[.d.]. .Iadd.d.sub.6.Iaddend.): .delta.
[ppm]=7.66 (s, 1H); 7.52 (t, 1H); 7.38 (dd, 2H); 7.20 (t, 1H);
7.10-6.78 (m, 6H); 5.33-5.26 (m, 1H); 3.51 (d.sub.b, 4H); 3.11
(d.sub.b, 4H); 2.61-2.55 (m, 2H).
Example 6
{8-Fluoro-2-[4-(1,3-benzodioxol-5-yl)-1-piperazinyl]-3-[3-(trifluoromethy-
l)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00128##
Starting with 173 mg (0.30 mmol) of the methyl ester from Example
36A, the general procedure [H] gives 79 mg (46% of theory) of
product.
HPLC (Method 1): R.sub.t=4.44 min
MS (ESI-pos): m/z=557.2 (M+H).sup.+
.sup.1H NMR (300 MHz, CDCl.sub.3): .delta. [ppm]=7.47 (s, 1H);
7.42-7.34 (m, 3H); 7.03-6.89 (m, 2H); 6.79 (d, 1H); 6.64 (d, 1H);
6.41 (d, 1H); 6.22 (dd, 1H); 5.87 (s, 2H); 5.20-5.15 (m, 1H); 3.59
(s.sub.b, 3H); 2.94-2.85 (m, 5H); 2.59 (dd, 1H).
Example 7
{6-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00129##
Starting with 42 mg (0.08 mmol) of the methyl ester from Example
21A, the general procedure [H] gives 34 mg (76% of theory) of
product.
HPLC (Method 1): R.sub.t=4.63 min
MS (ESI-pos): m/z=530.9 (M+H).sup.+
Example 8
{6-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
##STR00130##
Starting with 350 mg (0.64 mmol) of the ester from Example 22A, the
general procedure [H] gives 284 mg (83% of theory) of product.
HPLC (Method 1): R.sub.t=4.53 min
MS (ESI-pos): m/z=530.8 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.62 (s, 1H);
7.51-7.48 (m, 1H); 7.43-7.41 (d, 1H); 7.26-7.23 (m, 1H); 7.04-6.95
(m, 2H); 6.91-6.85 (m, 3H); 5.23 (dd, 1H); 3.55 (s.sub.b, 3H);
3.02-2.99 (m, 1H); 2.94 (s.sub.b, 4H); 2.80 (dd, 1H).
Example 9
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phen-
yl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
##STR00131##
Starting with 1.10 g (1.93 mmol) of the ester from Example 24A, the
general procedure [H] gives 1.04 g (91% of theory) of product.
Following the separation of enantiomers by Method 4, the product is
obtained as enantiomer A.
HPLC (Method 1): R.sub.t=4.68 min
MS (ESI-pos): m/z=526.9 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.61 (s, 1H);
7.49-7.38 (m, 3H); 7.10-6.89 (m, 4H); 6.71-6.65 (m, 3H); 5.26 (dd,
1H); 3.60-3.52 (m, 4H); 3.03-2.95 (m, 4H); 2.76 (dd, 1H); 2.57 (dd,
1H); 2.25 (s, 3H).
Example 10
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phe-
nyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
##STR00132##
Starting with 437 mg (0.79 mmol) of the ester from Example 26A, the
general procedure [H] gives 344 mg (72% of theory) of product.
HPLC (Method 1): R.sub.t=4.48 min
MS (ESI-pos): m/z=543.0 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.61 (s, 1H);
7.49-7.38 (m, 3H); 7.14-6.89 (m, 4H); 6.47-6.39 (m, 3H); 5.26 (dd,
1H); 3.72 (s, 1H); 3.60-3.54 (m, 4H); 3.07-3.00 (m, 4H); 2.77 (dd,
1H); 2.57 (dd, 1H).
Example 11
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-(t-
rifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
hydrochloride
##STR00133##
Starting with 1.03 g (1.75 mmol) of the crude product of the ester
from Example 27A, the general procedure [H] and chromatography
according to Method 5 followed by dissolution of the product in
methanol/1N hydrochloric acid and re-evaporation of the solvent
give 283 mg (22% of theory) of hydrochloride.
HPLC (Method 1): R.sub.t=4.58 min
MS (ESI-pos): m/z=575.2 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=8.17 (s, 0.66H);
7.69 (d, 1H); 7.55-7.30 (m, 1H); 7.27-7.24 (m, 2H); 7.16 (d, 0.6H);
7.09-7.04 (m, 2H); 5.33-5.27, 5.12-5.06 (2.times.m, 1H); 4.08-3.35
(m, 4H); 3.69 (s, 3H); 3.30-3.22 (m, 1H); 2.80-2.76 (m, 1H); 2.25
(s, 3H).
Example 12
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-(t-
rifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
hydrochloride
##STR00134##
Prior to the separation of enantiomers, 268 mg of the hydrochloride
from Example 11 are taken up in dichloromethane, and the organic
phase is extracted twice with saturated sodium bicarbonate
solution. The combined aqueous phases are extracted once with
dichloromethane, the combined organic phases are dried over sodium
sulphate and filtered and the solvent is removed under reduced
pressure. This gives 204 mg (86% of theory) of the free base. Using
this material, separation of enantiomers (Method 4), repurification
by preparative HPLC (Method 5) and subsequent dissolution of the
product in methanol/1N hydrochloric acid and re-evaporation of the
solvent gives 80 mg (78% of theory) of enantiomer A.
HPLC (Method 6): R.sub.t=4.66 min
MS (ESI-pos): m/z=575.2 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=8.17 (s, 0.66H);
7.69 (d, 1H); 7.45-7.30 (m, 1H); 7.24 (d, 2H); 7.15 (d, 0.7H);
7.08-7.01 (m, 2H); 5.32-5.27, 5.11-5.07 (2.times.m, 1H); 4.06-3.50
(m, 4H); 3.68 (s, 3H); 3.33-3.24 (m, 1H); 2.77-2.72 (m, 1H); 2.24,
2.23 (2.times.s, 3H).
Example 13
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-me-
thylphenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
hydrochloride
##STR00135##
Starting with 183 mg (0.34 mmol) of the crude product of the ester
from Example 28A, the general procedure [H] and chromatography
according to Method 5 followed by dissolution of the product in
methanol/1N hydrochloric acid and re-evaporation of the solvent
give 135 mg (67% of theory) of hydrochloride.
HPLC (Method 1): R.sub.t=4.67 min
MS (ESI-pos): m/z=521.2 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.69-7.42 (m, 4H);
7.25-7.06 (m, 5H); 6.93-6.78 (m, 1H); 5.24-5.21, 5.06-5.03
(2.times.m, 1H); 4.00-3.35 (m, 8H); 3.21-3.08 (m, 1H); 3.01-2.77
(m, 1H); 2.34, 2.20 (2.times.s, 3H); 2.26 (s, 3H).
Example 14
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoro-
methyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00136##
At room temperature, 179.6 mg (4.49 mmol) of sodium hydroxide are
added to 878 mg (1.5 mmol) of methyl
{8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoro-
methyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 31A) in
40 ml of dioxane, and the mixture is stirred at 50.degree. C. for 2
hours. The pH is then adjusted to 4-5. The product is filtered off,
washed with water and dried under reduced pressure.
Yield: 801 mg (93% of theory)
HPLC (Method 1): R.sub.t=4.5 min
MS (ESI-pos): m/z=573 (M+H).sup.+
Example 15
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoro-
methyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00137##
After separation of enantiomers (Method 11) of 500 mg of racemate
(Example 14), the crude product is purified by chromatography on
silica gel and then dissolved in 1N aqueous sodium hydroxide
solution and extracted with diethyl ether. Following acidification
with 1N hydrochloric acid, the product is filtered off and dried
under reduced pressure.
Yield: 105 mg (21% of theory)
MS (ESI-pos): m/z=573 (M+H).sup.+
.sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. [ppm]=2.4-2.5 (m, 1H);
2.7-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.7 (s, 3H); 3.7-3.9 (s.sub.b,
3H); 4.8-5.05 (s.sub.b, 1H); 6.3-6.4 (m, 2H); 6.4-6.5 (m, 1H);
6.8-7.65 (m, 6H); 12.5 (s.sub.b, 1H).
Alternatively, the target product is obtained by reacting the
enantiomerically pure ester from Example 43A according to the
general procedure [H]. Starting with 111 g (0.19 mol) of ester, 69
g (63% of theory) of target product are obtained.
Example 16
{8-Fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(triflu-
oromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00138##
In 40 ml of dioxane, 881 mg (1.49 mmol) of methyl
{8-fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(triflu-
oromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 32A)
and 178 mg (4.46 mmol) of sodium hydroxide are stirred at
50.degree. C. for 2 hours. Following acidification with 1N
hydrochloric acid, the product is filtered off with suction, washed
with water and dried under reduced pressure.
Yield: 775 mg (90% of theory)
HPLC (Method 1): R.sub.t=4.5 min
MS (ESI-pos): m/z=579 (M+H).sup.+
Example 17
{8-Fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(triflu-
oromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00139##
Following the separation of enantiomers (Method 12) of 500 mg (0.86
mmol) of racemate (Example 16), the crude product is purified by
chromatography on silica gel (dichloromethane,
dichloromethane/methanol 20:1, 10:1), dissolved in 1N aqueous
sodium hydroxide solution and extracted with diethyl ether. Using
1N hydrochloric acid the aqueous phase is adjusted to pH 4-5, and
the product is filtered off, washed with water and dried under
reduced pressure.
Yield: 86 mg (17% of theory)
MS (ESI-pos): m/z=579 (M+H).sup.+
.sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. [ppm]=2.6-3.1 (m, 6H);
3.25-3.6 (m, 4H); 3.75 (s.sub.b, 3H); 4.85 (s.sub.b, 1H); 6.6-6.7
(m, 1H); 6.7-7.7 (m, 9H); 12.5 (s.sub.b, 1H).
Example 18
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00140##
In 800 ml of dioxane, 15 g (26.11 mmol) of methyl
{8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 30A) and
3.13 g (78.32 mmol) of sodium hydroxide are stirred at 50.degree.
C. for 4 hours. Following distillative removal of the solvent, the
residue is dissolved in 500 ml of water and acidified and the
precipitate is filtered off with suction. The product is washed
with water and dried under reduced pressure.
Yield: 14.5 g (99% of theory)
HPLC (Method 1): R.sub.t=4.5 min
MS (ESI-pos): m/z=561 (M+H).sup.+
Example 19
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00141##
14.2 g (25.33 mmol) of racemate (Example 18) are separated (Method
13). The crude product is dissolved in 250 ml of 0.5N sodium
hydroxide solution and then purified by extraction with diethyl
ether. After acidification of the aqueous phase with hydrochloric
acid, the product is filtered off, washed with water and dried
under reduced pressure.
Yield: 5.85 g (41% of theory)
MS (ESI-pos): m/z=561 (M+H).sup.+
HPLC (Method 1): R.sub.t=4.5 min
.sup.1H NMR (400 MHz, DMSO-D.sub.6): .delta. [ppm]=2.6-3.0 (m, 6H);
3.3-3.6 (m, 4H); 3.6-4.0 (s.sub.b, 3H); 4.8-5.2 (s.sub.b, 1H);
6.7-7.75 (m, 10H); 12.2-12.8 (s.sub.b, 1H).
Alternatively, the target product is obtained by reacting the
enantiomerically pure ester from Example 42A according to the
general procedure .[.[11].]. .Iadd.[H].Iaddend.. Starting with 120
g (0.21 mol) of ester, 96 g (81% of theory) of target product are
obtained.
Example 20
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00142##
In 40 ml of dioxane, 892 mg (1.56 mmol) of methyl
{8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 33A) and
187.6 mg (4.69 mmol) of sodium hydroxide are stirred at 50.degree.
C. for 2 hours. Following removal of the solvent, the residue is
taken up in water and adjusted to pH 4-5 using 1N hydrochloric
acid. The product is filtered off and then washed with water and
dried under reduced pressure.
Yield: 788 mg (91% of theory)
MS (ESI-pos): m/z=557 (M+H).sup.+
HPLC (Method 6): R.sub.t=4.5 min
Example 21
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00143##
The separation of enantiomers (Method 13) is carried out using 500
mg (0.9 mmol) of racemate (Example 20). The crude product is then
dissolved in 1N aqueous sodium hydroxide solution, the solution is
extracted with diethyl ether and the aqueous phase is adjusted to
pH 4-5 using 1N hydrochloric acid. The product is filtered off with
suction, washed with water and dried under reduced pressure.
Yield: 104 mg (21% of theory)
MS (ESI-pos): m/z=557 (M+H).sup.+
.sup.1H NMR (400 MHz, .[.DMSO d.sub.6.].
.Iadd.DMSO-d.sub.6.Iaddend.): .delta. [ppm]=2.2 (s.sub.b, 3H);
2.35-2.5 (m, 1H); 2.6-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.8 (s.sub.b,
3H); 4.9 (s.sub.b, 1H); 6.5-6.7 (m, 3H); 6.8-7.7 (m, 7H); 12.6
(s.sub.b, 1H).
Example 22
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chloropheny-
l]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
##STR00144##
Starting with 621 mg (1.15 mmol) of the ester from Example 29A, the
general procedure [H] and purification by preparative HPLC (Method
5) and coevaporation with .[.methanol/N.]. .Iadd.methanol/1N
.Iaddend.hydrochloric acid give 330 mg (51% of theory) of
product.
HPLC (Method 1): R.sub.t=4.58 min
MS (ESI-pos): m/z=527.0 (M+H-HCl).sup.+
Example 23
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chloropheny-
l]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
##STR00145##
Starting with 320 mg (0.06 mmol) of the racemate from Example 22,
chromatographic separation of enantiomers (Method 4) and subsequent
dissolution of the product in methanol/1N hydrochloric acid and
re-evaporation of the solvent give 174 mg (50% of theory) of
hydrochloride.
HPLC (Method 1): R.sub.t=4.51 min
MS (ESI-pos): m/z=527.1 (M+H-HCl).sup.+
.sup.1H NMR (400 MHz, CD.sub.3CN): .delta. [ppm]=7.29 (dd, 1H);
7.19-7.11 (m, 2H); 7.01-6.94 (m, 4H); 6.87-6.83 (m, 2H); 5.08 (t,
1H); 3.67 (s, 3H); 3.56 (s, 4H); 3.03-2.92 (m, 5H); 2.72 (dd,
1H).
Example 24
{8-Fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00146##
In 15 ml of dioxane, 117 mg (0.2 mmol) of methyl
{8-fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluorom-
ethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 34A) are
mixed with 0.61 ml of 1N aqueous sodium hydroxide solution, and the
mixture is stirred at 50.degree. C. for 3 hours. After removal of
the solvent, the residue is taken up in water and the mixture is
adjusted to pH .[.34.]. .Iadd.3-4 .Iaddend.using 1N hydrochloric
acid. The precipitate is filtered off with suction, washed with
water and dried under reduced pressure.
Yield: 76 mg (67% of theory)
HPLC (Method 1): R.sub.t=4.6 min
MS (ESI-pos): m/z=561 (M+H).sup.+
Example 25
{8-Fluoro
-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoro-
methyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00147##
52 mg (0.09 mmol) of the racemate (Example 24) are separated into
the enantiomers (Method 13). The crude product is then purified by
chromatography on silica gel (acetic acid, dichloromethane/methanol
10:1) and dried under reduced pressure.
Yield: 12.3 mg (24% of theory)
LC-MS (Method 7): R.sub.t=2.50 min
MS (ESI-pos): m/z=561 (M+H).sup.+
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm]=2.35-2.5 (m,
1H); 2.7-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.8 (s.sub.b, 3H); 4.8-4.9
(m, 1H); 6.45-6.6 (m, 1H); 6.6-6.7 (m, 2H); 6.8-6.9 (m, 2H);
6.98-7.1 (m, 1H); 7.1-7.6 (m, 4H); 12.4 (s.sub.b, 1H).
Examples 26 to 34 and 36 to 89 of Table 2 can be prepared from the
corresponding starting materials using the general procedures [A]
to [H], and Example 35 can be prepared as described below in Table
2.
TABLE-US-00002 TABLE 2 Molecular Starting Exam- weight material
R.sub.4 HPLC ple No. Structure [g/mol] Example [min] Method MS 26
##STR00148## 597.0 50A 4.53 1 561 [M + H - HCl].sup.+ 27
##STR00149## 592.0 51A 4.22 1 556 [M + H - HCl].sup.+ 28
##STR00150## 588.0 52A 4.36 1 552 [M + H - HCl].sup.+ 29
##STR00151## 608.4 53A 4.37 1 572 [M + H - HCl].sup.+ 30
##STR00152## 584.9 54A 4.54 1 548 [M + H - HCl].sup.+ 31
##STR00153## 604.0 55A 4.27 1 568 [M + H - HCl].sup.+ 32
##STR00154## 537.5 56A 4.30 1 538 [M + H - HCl].sup.+ 33
##STR00155## 517.5 57A 4.28 1 518 [M + H - HCl].sup.+ 34
##STR00156## 537.5 58A 4.41 1 538 [M + H - HCl].sup.+ 35
##STR00157## 565.0 89 4.47 1 529 [M + H].sup.+ 36 ##STR00158##
584.9 60A 4.61 1 549 [M + H].sup.+ 37 ##STR00159## 502.6 61A 4.6 1
503 [M + H].sup.+ 38 ##STR00160## 590.6 62A 4.6 6 591 [M + H].sup.+
39 ##STR00161## 590.6 63A 4.53 1 591 [M + H].sup.+ 40 ##STR00162##
576.6 64A 4.5 6 577 [M + H].sup.+ 41 ##STR00163## 594.6 65A 4.5 6
595 [M + H].sup.+ 42 ##STR00164## 588.6 66A 4.4 6 589 [M + H].sup.+
43 ##STR00165## 572.6 67A 4.5 6 573 [M + H].sup.+ 44 ##STR00166##
548.6 68A 4.9 1 549 [M + H].sup.+ 45 ##STR00167## 548.5 69A 4.67 1
549 [M + H].sup.+ 46 ##STR00168## 566.5 70A 4.60 1 567 [M +
H].sup.+ 47 ##STR00169## 566.6 71A 4.9 1 567 [M + H].sup.+ 48
##STR00170## 560.7 72A 4.8 1 561 [M + H].sup.+ 49 ##STR00171##
544.7 73A 5.0 1 545 [M + H].sup.+ 50 ##STR00172## 576.6 74A 4.6 1
577 [M + H].sup.+ 51 ##STR00173## 578.5 75A 4.7 1 579 [M + H].sup.+
52 ##STR00174## 532.6 76A 4.6 1 561 [M + H].sup.+ 53 ##STR00175##
524.5 77A 4.5 1 525 [M + H].sup.+ 54 ##STR00176## 574.6 78A 4.7 1
561 [M + H].sup.+ 55 ##STR00177## 567.6 79A 4.3 1 568 [M + H].sup.+
56 ##STR00178## 494.5 80A 2.77 10 495 [M + H].sup.+ 57 ##STR00179##
490.6 81A 1.94 9 491 [M + H].sup.+ 58 ##STR00180## 507.0 82A 1.97 9
507 [M + H].sup.+ 59 ##STR00181## 511.0 83A 1.93 9 511 [M +
H].sup.+ 60 ##STR00182## 486.6 84A 1.90 9 487 [M + H].sup.+ 61
##STR00183## 526.5 85A 4.69 1 527 [M + H].sup.+ 62 ##STR00184##
545.0 86A 3.57 8 547 [M + H].sup.+ 63 ##STR00185## 542.5 87A 3.37 8
543 [M + H].sup.+ 64 ##STR00186## 574.0 88A 4.43 1 538 [M + H -
HCl].sup.+ 65 ##STR00187## 590.4 89A 4.58 1 554 [M + H - HCl].sup.+
66 ##STR00188## 586.0 90A 4.41 1 550 [M + H - HCl].sup.+ 67
##STR00189## 594.5 91A 4.82 1 595 [M + H].sup.+ 68 ##STR00190##
548.5 92A 4.66 1 549 [M + H].sup.+ 69 ##STR00191## 562.5 93A 4.74 1
563 [M + H].sup.+ 70 ##STR00192## 530.5 94A 4.62 1 531 [M +
H].sup.+ 71 ##STR00193## 591.4 95A 4.76 1 591 [M + H].sup.+ 72
##STR00194## 548.5 96A 4.63 1 549 [M + H].sup.+ 73 ##STR00195##
523.0 97A 4.65 1 523 [M + H].sup.+ 74 ##STR00196## 543.4 98A 4.67 6
543 [M + H].sup.+ 75 ##STR00197## 539.0 99A 4.56 6 539 [M +
H].sup.+ 76 ##STR00198## 559.5 100A 4.63 6 523 [M + H - HCl].sup.+
77 ##STR00199## 506.6 101A 4.52 6 507 [M + H].sup.+ 78 ##STR00200##
539.0 102A 4.63 6 503 [M + H - HCl].sup.+ 79 ##STR00201## 555.0
103A 4.41 6 519 [M + H - HCl].sup.+ 80 ##STR00202## 577.5 104A 4.53
6 541 [M + H - HCl].sup.+ 81 ##STR00203## 541.0 105A 4.68 1 541 [M
+ H].sup.+ 82 ##STR00204## 537.5 45A 4.52 1 538 [M + H].sup.+ 83
##STR00205## 530.5 106A 4.51 1 531 [M + H].sup.+ 84 ##STR00206##
526.5 107A 4.70 1 527 [M + H].sup.+ 85 ##STR00207## 583.4 108A 4.61
1 547 [M + H - HCl].sup.+ 86 ##STR00208## 585.0 109A 4.82 1 549 [M
+ H - HCl].sup.+ 87 ##STR00209## 530.5 110A 4.54 1 531 [M +
H].sup.+ 88 ##STR00210## 570.6 111A 4.54 1 571 [M + H].sup.+ 89
##STR00211## 579.0 59A 4.60 1 543 [M + H - HCl].sup.+
Example 35
{2-[4-(4-Fluorophenyl)piperazin-1-yl]-8-hydroxy-3-[3-(trifluoromethyl)phe-
nyl]-3,4-dihydroquinazolin-4-yl}acetic acid
##STR00212##
80 mg (0.14 mmol) of the methyl ether (Example 89) are dissolved in
2 ml of dichloromethane, and 0.41 mmol of a 1M solution of boron
tribromide in dichloromethane is added at 0.degree. C. The mixture
is stirred at room temperature for 16 hours, a further 0.82 mmol of
the boron tribromide solution is added, followed by a further 1.23
mmol after 24 hours. The reaction mixture is stirred at room
temperature for 24 hours and then poured onto ice, and 5 ml of a 1N
aqueous hydrochloric acid solution are added. The mixture is
extracted with 25 ml of ethyl acetate. The organic phase is washed
with a saturated aqueous sodium chloride solution, dried over
sodium sulphate, concentrated and purified by preparative HPLC.
This gives 50 mg (63% of theory) of product.
HPLC (Method 1): R.sub.t=4.47 min
MS (ESI-pos): m/z=529 (M+H-HCl).sup.+
Example 90
{7-Hydroxycarbonyl-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[5-(trifluorome-
thyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
##STR00213##
100 mg (0.16 mmol) of the ester from Example 45A are suspended in
semiconcentrated hydrochloric acid, and the reaction mixture is
stirred at 90.degree. C. for 42 hours. After cooling, the mixture
is adjusted to pH=4 using 20% strength aqueous sodium hydroxide
solution and the precipitate that is formed is filtered off, washed
with water and dried under reduced pressure.
Yield: 64 mg (66% of theory)
HPLC (Method 1): R.sub.t=4.38 min
MS (ESI-pos): m/z=557 (M+H).sup.+
Example 91
{6-(Aminocarbonyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluorome-
thyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid
hydrochloride
##STR00214##
500 mg (0.8 mmol) of the tert-butyl ester from Example 49A are
suspended with 8 ml of a 4M solution of hydrogen chloride in
dioxane, and the reaction mixture is stirred at room temperature
for 16 hours. The suspension is concentrated and dried under
reduced pressure.
Yield: 564 mg (99% of theory)
HPLC (Method 1): R.sub.t=4.25 min
MS (ESI-pos): m/z=556 (M+H-HCl).sup.+
.sup.1H NMR (300 MHz, DMSO-D.sub.6): .delta. [ppm]=12.94 (brs, 1H);
8.11 (s, 1H); 8.03-7.95 (m, 2H); 7.92-7.65 (m, 4H); 7.09-6.91 (m,
4H); 5.50 (dd, 1H); 4.38-4.12 (m, 4H); 3.17-3.06 (m, 5H); 2.81 (dd,
1H).
B. Assessment of the Physiological Activity
The in vitro effect of the compounds of the invention can be shown
in the following assays:
Anti-HCMV (Anti-Human Cytomegalovirus) Cytopathogenicity Tests
The test compounds are employed as 50 millimolar (mM) solutions in
dimethyl sulphoxide (DMSO). Ganciclovir.RTM., Foscarnet.RTM. and
Cidofovir.RTM. are used as reference compounds. After addition of
in each case 2 .mu.l of the 50, 5, 0.5 and 0.05 mM DMSO stock
solutions to 98 .mu.l portions of cell culture medium in row 2 A-H
for duplicate determinations, 1:2 dilutions are carried out with 50
.mu.l portions of medium up to row 11 of the 96-well plate. The
wells in rows 1 and 12 each contain 50 .mu.l of medium. In 150
.mu.l of a suspension of 1.times.10.sup.4 cells (human prepuce
fibroblasts [NHDF]) are pipetted into each of the wells (row 1=cell
control) and, in rows 2-12, a mixture of HCMV-infected and
uninfected NHDF cells (M.O.I.=0.001-0.002), i.e. 1-2 infected cells
per 1000 uninfected cells. Row 12 (without substance) serves as
virus control. The final test concentrations are 250-0.0005 .mu.M.
The plates are incubated at 37.degree. C./5% CO.sub.2 for 6 days,
i.e. until all the cells are infected in the virus controls (100%
cytopathogenic effect [CPE]). The wells are then fixed and stained
by adding a mixture of formalin and Giemsa's dye (30 minutes),
washed with double-distilled water and dried in a drying oven at
50.degree. C. The plates are then assessed visually using an
overhead microscope (Plaque Multiplier from Technomara).
The following data can be acquired from the test plates:
CC.sub.50 (NHDF)=substance concentration in .mu.M at which no
visible cytostatic effects on the cells are evident by comparison
with the untreated cell control;
EC.sub.50 (HCMV)=substance concentration in .mu.M which inhibits
the CPE (cytopathic effect) by 50% compared with the untreated
virus control;
SI (selectivity index)=CC.sub.50 (NHDF)/EC.sub.50 (HCMV).
Representative in vitro data for the effects of the compounds of
the invention are shown in Table A:
TABLE-US-00003 TABLE A NHDF Example CC.sub.50 HCMV SI No. [.mu.M]
EC.sub.50 [.mu.M] HCMV 2 12 0.016 750 9 15 0.02 750 15 31 0.002
15500 19 17 0.002 8947 23 24 0.002 12632 29 47 0.07 671
The suitability of the compounds of the invention for the treatment
of HCMV infections can be shown in the following animal model:
HCMV Xenograft Gelfoam.RTM. Model
Animals:
3-4-week old female immunodeficient mice (16-18 g), Fox Chase SCID
or Fox Chase SCID-NOD or SCID beige, are purchased from commercial
breeders (Taconic M+B, Jackson USA). The animals are housed under
sterile conditions (including bedding and feed) in isolators.
Virus growing:
Human cytomegalovirus (HCMV), Davis or AD169 strain, is grown in
vitro on human embryonic prepuce fibroblasts (NHDF cells). After
the NHDF cells have been infected with a multiplicity of infection
(M.O.I.) of 0.01-0.03, the virus-infected cells are harvested 5-10
days later and stored in the presence of minimal essential medium
(MEM), 10% fetal calf serum (FCS) with 10% DMSO at .[.40.degree.
C.]. .Iadd.-40.degree. C..Iaddend.. After serial ten-fold dilutions
of the virus-infected cells, the titer is determined on 24-well
plates of confluent NHDF cells after vital staining with Neutral
Red.
Preparation of the Sponges, Transplantation, Treatment and
Evaluation:
Collagen sponges 1.times.1.times.1 cm in size (Gelfoam.RTM.; from
Peasel & Lorey, order No. 407534; K. T. Chong et al., Abstracts
of 39.sup.th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 1999, p. 439) are initially wetted with
phosphate-buffered saline (PBS), the trapped air bubbles are
removed by degassing, and then stored in MEM+10% FCS.
1.times.10.sup.6 virus-infected NHDF cells (infection with HCMV
Davis or HCMV AD169 M.O.I. =0.01) are detached 3 hours after
infection and added in a drop of 20 .mu.l of MEM, 10% of FCS, to a
moist sponge. About 16 hours later, the infected sponges are
incubated with 25 .mu.l of PBS/0.1% BSA/l mM DTT with 5 ng/.mu.l
basic fibroblast growth factor (bFGF). For the transplantation, the
immunodeficient mice are anaesthetized with Avertin or a
ketamine/xylazine/azepromazine mixture, the fur on the back is
removed using a shaver, the epidermis is opened 1-2 cm, unstressed
and the moist sponges are transplanted under the dorsal skin. The
surgical wound is closed with tissue glue. 6 hours after the
transplantation, the mice can be treated for the first time (on the
day of the operation, there is one treatment). The next days, over
a period of 8 days, the mice are treated with substance orally
three times a day (7.00 h and 14.00 h and 19.00 h), two times a day
(8.00 h and 18.00 h) or once a day (14.00 h). The daily dose is,
for example 3 or 10 or 30 or 60 or 100 mg/kg of body weight, the
volume administered is 10 ml/kg of body weight. The substances are
formulated in the form of a 0.5% strength Tylose suspension with 2%
DMSO or a 0.5% strength Tylose suspension. 9 days after
transplantation and 16 hours after the last administration of
substance, the animals are painlessly sacrificed and the sponge is
removed. The virus-infected cells are released from the sponge by
collagenase digestion (330 U/1.5 ml) and stored in the presence of
MEM, 10% fetal calf serum, 10% DMSO at -140.degree. C. Evaluation
takes place after serial ten-fold dilutions of the virus-infected
cells by determining the titer on 24-well plates of confluent NHDF
cells after vital staining with Neutral Red. The number of infected
cells or infectious virus particles (infectious centre assay) after
the substance treatment compared with the placebo-treated control
is determined.
CYP Inhibition Assay
To investigate the mechanism-based (irreversible) inhibition of
CYP3A4, different concentrations of the test substance are
incubated with human liver microsomes (2 mg/ml of microsomal
protein) in potassium phosphate buffer pH 7.4 with addition of an
NADPH-generating system (NADP+, glucose 6-phosphate, glucose
6-phosphate dehydrogenase) at 37.degree. C. At various points of
time, 2 aliquots are taken from the incubation.
The first aliquot is incubated 1:50 in a new incubation solution
(phosphate buffer, NADPH-generating system and 10 .mu.M of
Midazolam) at 37.degree. C. for a further 10 min. The incubation is
then stopped using acetonitrile on ice, the protein is pelleted in
a centrifuge at 15 000 g and the supernatant is analysed for
formation of 1'-hydroxyimidazolam using standard HPLC/MS
methods.
The second aliquot is stopped using acetonitrile on ice and
analysed for remaining test substance using HPLC/UV/MS.
The two sets of analytical data are determined for
irreversible-inhibition-typical parameters (k.sub.inact, K.sub.i
and partition ratio r), and using these data, the test substance is
evaluated (cf. A. Madan, et al., in A. D. Rodrigues (ed.)
"Drug-Drug Interaction" in "Drugs and the Pharmaceutical Science",
Vol. 116, ISBN 0-8247-0283.2, Marcel Dekker Inc., New York,
2002.).
C. Exemplary Embodiments of Pharmaceutical Compositions
The compounds of the invention can be converted into pharmaceutical
preparations in the following ways:
Tablet:
Composition:
100 mg of the compound of Example 1, 50 mg of lactose
(monohydrate), 50 mg of corn starch (native), 10 mg of
polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany)
and 2 mg of magnesium stearate.
Tablet weight 212 mg. Diameter 8 mm, radius of curvature 12 mm.
Production:
The mixture of active ingredient, lactose and starch is granulated
with a 5% strength solution (m/m) of the PVP in water. The granules
are then dried and mixed with the magnesium stearate for 5 min.
This mixture is compressed using a conventional tablet press (see
above for format of the tablet). A guideline for the compressive
force used for the compression is 15 kN.
Suspension which can be Administered Orally:
Composition:
1000 mg of the compound of Example 1, 1000 mg of ethanol (96%), 400
mg of Rhodigel (xanthan gum from FMC, Pennsylvania, USA) and 99 g
of water.
10 ml of oral suspension are equivalent to a single dose of 100 mg
of the compound of the invention.
Production:
The Rhodigel is suspended in ethanol, and the active ingredient is
added to the suspension. The water is added while stirring. The
mixture is stirred for about 6 h until the swelling of the Rhodigel
is complete.
Solution which can be Administered Intravenously:
Composition:
10-500 mg of the compound of Example 1, 15 g of polyethylene glycol
400 and 250 g of water for injection.
Production:
The compound of Example 1 is dissolved together with polyethylene
glycol 400 in the water with stirring. The solution is sterilized
by filtration (pore diameter 0.22 .mu.m) and dispensed under
aseptic conditions into heat-sterilized infusion bottles. The
latter are closed with infusion stoppers and trimmed caps.
* * * * *
References